Experimental Factor Ontology (EFO) Information | |
Identifier | EFO_0000305 |
Description | A carcinoma that arises from epithelial cells of the breast [MONDO: DesignPattern] | Trait category |
Cancer
|
Synonyms |
9 synonyms
|
Mapped terms |
9 mapped terms
|
Child trait(s) | 7 child traits |
Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS000001 (PRS77_BC) |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
Breast cancer | breast carcinoma | 77 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000001/ScoringFiles/PGS000001.txt.gz |
PGS000002 (PRS77_ERpos) |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
ER-positive breast cancer | estrogen-receptor positive breast cancer | 77 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000002/ScoringFiles/PGS000002.txt.gz |
PGS000003 (PRS77_ERneg) |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
ER-negative breast cancer | estrogen-receptor negative breast cancer | 77 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000003/ScoringFiles/PGS000003.txt.gz |
PGS000004 (PRS313_BC) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Breast cancer | breast carcinoma | 313 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000004/ScoringFiles/PGS000004.txt.gz | |
PGS000005 (PRS313_ERpos) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
ER-positive breast cancer | estrogen-receptor positive breast cancer | 313 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000005/ScoringFiles/PGS000005.txt.gz | |
PGS000006 (PRS313_ERneg) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
ER-negative breast cancer | estrogen-receptor negative breast cancer | 313 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000006/ScoringFiles/PGS000006.txt.gz | |
PGS000007 (PRS3820_BC) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Breast cancer | breast carcinoma | 3,820 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000007/ScoringFiles/PGS000007.txt.gz | |
PGS000008 (PRS3820_ERpos) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
ER-positive breast cancer | estrogen-receptor positive breast cancer | 3,820 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000008/ScoringFiles/PGS000008.txt.gz | |
PGS000009 (PRS3820_ERneg) |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
ER-negative breast cancer | estrogen-receptor negative breast cancer | 3,820 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000009/ScoringFiles/PGS000009.txt.gz | |
PGS000015 (GPS_BC) |
PGP000006 | Khera AV et al. Nat Genet (2018) |
Breast cancer | breast carcinoma | 5,218 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000015/ScoringFiles/PGS000015.txt.gz | |
PGS000028 (PRS) |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Breast cancer | breast carcinoma | 83 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000028/ScoringFiles/PGS000028.txt.gz |
PGS000029 (PRS_AS) |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Breast cancer | breast carcinoma | 76 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000029/ScoringFiles/PGS000029.txt.gz |
PGS000045 (BCPRS_Overall) |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Breast cancer | breast carcinoma | 88 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000045/ScoringFiles/PGS000045.txt.gz |
PGS000046 (BCPRS_ER+) |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Estrogen receptor [ER]-positive breast cancer | estrogen-receptor positive breast cancer | 87 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000046/ScoringFiles/PGS000046.txt.gz |
PGS000047 (BCPRS_ER-) |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Estrogen receptor [ER]-negative breast cancer | estrogen-receptor negative breast cancer | 53 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000047/ScoringFiles/PGS000047.txt.gz |
PGS000050 (PRS44) |
PGP000035 | Wen W et al. Breast Cancer Res (2016) |
Breast cancer | breast carcinoma | 44 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000050/ScoringFiles/PGS000050.txt.gz |
PGS000051 (PRS67) |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Breast cancer | breast carcinoma | 67 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000051/ScoringFiles/PGS000051.txt.gz |
PGS000052 (sPRS161) |
PGP000037 | Lakeman IMM et al. J Med Genet (2019) |
Breast cancer | breast carcinoma | 161 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000052/ScoringFiles/PGS000052.txt.gz | |
PGS000072 (CC_Breast) |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Breast cancer | breast carcinoma | 187 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000072/ScoringFiles/PGS000072.txt.gz |
PGS000153 (cGRS_Breast) |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Breast cancer | breast carcinoma | 66 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000153/ScoringFiles/PGS000153.txt.gz |
PGS000212 (PRS330_LumA) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (luminal A-like) | luminal A breast carcinoma | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000212/ScoringFiles/PGS000212.txt.gz |
PGS000213 (PRS330_LumBHER2neg) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (luminal B/HER2-negative-like) | HER2 negative breast carcinoma | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000213/ScoringFiles/PGS000213.txt.gz |
PGS000214 (PRS330_LumB) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (luminal B-like) | luminal B breast carcinoma | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000214/ScoringFiles/PGS000214.txt.gz |
PGS000215 (PRS330_HER2) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (HER2-enriched-like) | HER2 Positive Breast Carcinoma | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000215/ScoringFiles/PGS000215.txt.gz |
PGS000216 (PRS330_TN) |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Breast cancer intrinsic-like subtype (triple negative) | triple-negative breast cancer | 330 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000216/ScoringFiles/PGS000216.txt.gz |
PGS000317 (PRS180) |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Breast cancer | breast carcinoma | 180 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000317/ScoringFiles/PGS000317.txt.gz |
PGS000332 (PRS_BC) |
PGP000100 | Mars N et al. Nat Med (2020) |
Breast cancer | breast carcinoma | 6,390,808 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000332/ScoringFiles/PGS000332.txt.gz | |
PGS000335 (BC_PRSCS) |
PGP000102 | Mars N et al. Nat Commun (2020) |
Breast cancer | breast carcinoma | 1,079,089 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000335/ScoringFiles/PGS000335.txt.gz |
PGS000344 (PRS287_BC) |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Breast cancer | breast carcinoma | 287 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000344/ScoringFiles/PGS000344.txt.gz | |
PGS000345 (PRS229_BC) |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Breast cancer | breast carcinoma | 229 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000345/ScoringFiles/PGS000345.txt.gz | |
PGS000346 (PRS287_ERneg) |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Estrogen receptor negative breast cancer | estrogen-receptor negative breast cancer | 287 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000346/ScoringFiles/PGS000346.txt.gz | |
PGS000347 (PRS287_ERpos) |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Estrogen receptor positive breast cancer | estrogen-receptor positive breast cancer | 287 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000347/ScoringFiles/PGS000347.txt.gz | |
PGS000472 (PRSWEB_PHECODE174.1_20001-1002_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 22 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000472/ScoringFiles/PGS000472.txt.gz | |
PGS000473 (PRSWEB_PHECODE174.1_20001-1002_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,111,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000473/ScoringFiles/PGS000473.txt.gz | |
PGS000474 (PRSWEB_PHECODE174.1_20001-1002_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 68 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000474/ScoringFiles/PGS000474.txt.gz | |
PGS000475 (PRSWEB_PHECODE174.1_20001-1002_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 30,041 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000475/ScoringFiles/PGS000475.txt.gz | |
PGS000476 (PRSWEB_PHECODE174.1_C3-BREAST-3_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 32 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000476/ScoringFiles/PGS000476.txt.gz | |
PGS000477 (PRSWEB_PHECODE174.1_C3-BREAST-3_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,111,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000477/ScoringFiles/PGS000477.txt.gz | |
PGS000478 (PRSWEB_PHECODE174.1_C3-BREAST-3_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 120 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000478/ScoringFiles/PGS000478.txt.gz | |
PGS000479 (PRSWEB_PHECODE174.1_C3-BREAST-3_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 2,267 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000479/ScoringFiles/PGS000479.txt.gz | |
PGS000480 (PRSWEB_PHECODE174.1_C50_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 20 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000480/ScoringFiles/PGS000480.txt.gz | |
PGS000481 (PRSWEB_PHECODE174.1_C50_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,111,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000481/ScoringFiles/PGS000481.txt.gz | |
PGS000482 (PRSWEB_PHECODE174.1_C50_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 42 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000482/ScoringFiles/PGS000482.txt.gz | |
PGS000483 (PRSWEB_PHECODE174.1_C50_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 4,047 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000483/ScoringFiles/PGS000483.txt.gz | |
PGS000484 (PRSWEB_PHECODE174.1_D05_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 25 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000484/ScoringFiles/PGS000484.txt.gz | |
PGS000485 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 62 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000485/ScoringFiles/PGS000485.txt.gz | |
PGS000486 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 86 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000486/ScoringFiles/PGS000486.txt.gz | |
PGS000487 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 62 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000487/ScoringFiles/PGS000487.txt.gz | |
PGS000488 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 79 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000488/ScoringFiles/PGS000488.txt.gz | |
PGS000489 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000489/ScoringFiles/PGS000489.txt.gz | |
PGS000490 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000490/ScoringFiles/PGS000490.txt.gz | |
PGS000491 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000491/ScoringFiles/PGS000491.txt.gz | |
PGS000492 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,120,410 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000492/ScoringFiles/PGS000492.txt.gz | |
PGS000493 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 217 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000493/ScoringFiles/PGS000493.txt.gz | |
PGS000494 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 49 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000494/ScoringFiles/PGS000494.txt.gz | |
PGS000495 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 18,866 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000495/ScoringFiles/PGS000495.txt.gz | |
PGS000496 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 41,744 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000496/ScoringFiles/PGS000496.txt.gz | |
PGS000497 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 257 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000497/ScoringFiles/PGS000497.txt.gz | |
PGS000498 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 257 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000498/ScoringFiles/PGS000498.txt.gz | |
PGS000499 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000499/ScoringFiles/PGS000499.txt.gz | |
PGS000500 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,120,410 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000500/ScoringFiles/PGS000500.txt.gz | |
PGS000501 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,142 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000501/ScoringFiles/PGS000501.txt.gz | |
PGS000502 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 747 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000502/ScoringFiles/PGS000502.txt.gz | |
PGS000503 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 61,635 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000503/ScoringFiles/PGS000503.txt.gz | |
PGS000504 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 148,560 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000504/ScoringFiles/PGS000504.txt.gz | |
PGS000505 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 334 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000505/ScoringFiles/PGS000505.txt.gz | |
PGS000506 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 334 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000506/ScoringFiles/PGS000506.txt.gz | |
PGS000507 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,140 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000507/ScoringFiles/PGS000507.txt.gz | |
PGS000508 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,120,410 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000508/ScoringFiles/PGS000508.txt.gz | |
PGS000509 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 3,038 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000509/ScoringFiles/PGS000509.txt.gz | |
PGS000510 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,682 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000510/ScoringFiles/PGS000510.txt.gz | |
PGS000511 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 118,388 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000511/ScoringFiles/PGS000511.txt.gz | |
PGS000512 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 286,144 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000512/ScoringFiles/PGS000512.txt.gz | |
PGS000513 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 41 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000513/ScoringFiles/PGS000513.txt.gz | |
PGS000514 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,119,237 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000514/ScoringFiles/PGS000514.txt.gz | |
PGS000515 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 84 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000515/ScoringFiles/PGS000515.txt.gz | |
PGS000516 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 6,977 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000516/ScoringFiles/PGS000516.txt.gz | |
PGS000517 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000517/ScoringFiles/PGS000517.txt.gz | |
PGS000518 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 10 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000518/ScoringFiles/PGS000518.txt.gz | |
PGS000519 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,115,376 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000519/ScoringFiles/PGS000519.txt.gz | |
PGS000520 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,116,435 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000520/ScoringFiles/PGS000520.txt.gz | |
PGS000521 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 9 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000521/ScoringFiles/PGS000521.txt.gz | |
PGS000522 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 14 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000522/ScoringFiles/PGS000522.txt.gz | |
PGS000523 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 270 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000523/ScoringFiles/PGS000523.txt.gz | |
PGS000524 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 2,708 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000524/ScoringFiles/PGS000524.txt.gz | |
PGS000525 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 86 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000525/ScoringFiles/PGS000525.txt.gz | |
PGS000526 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 86 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000526/ScoringFiles/PGS000526.txt.gz | |
PGS000527 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,115,436 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000527/ScoringFiles/PGS000527.txt.gz | |
PGS000528 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,116,495 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000528/ScoringFiles/PGS000528.txt.gz | |
PGS000529 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 310 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000529/ScoringFiles/PGS000529.txt.gz | |
PGS000530 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 174 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000530/ScoringFiles/PGS000530.txt.gz | |
PGS000531 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 98,026 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000531/ScoringFiles/PGS000531.txt.gz | |
PGS000532 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 12,277 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000532/ScoringFiles/PGS000532.txt.gz | |
PGS000533 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 110 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000533/ScoringFiles/PGS000533.txt.gz | |
PGS000534 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 110 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000534/ScoringFiles/PGS000534.txt.gz | |
PGS000535 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,115,484 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000535/ScoringFiles/PGS000535.txt.gz | |
PGS000536 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 1,116,546 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000536/ScoringFiles/PGS000536.txt.gz | |
PGS000537 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 363 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000537/ScoringFiles/PGS000537.txt.gz | |
PGS000538 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 85 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000538/ScoringFiles/PGS000538.txt.gz | |
PGS000539 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 18,356 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000539/ScoringFiles/PGS000539.txt.gz | |
PGS000540 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Breast cancer (female) | breast carcinoma | 7,118 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000540/ScoringFiles/PGS000540.txt.gz | |
PGS000773 (PRS179_BC) |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Breast cancer | breast carcinoma | 179 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000773/ScoringFiles/PGS000773.txt.gz |
PGS000774 (PRS179_ERpos) |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Estrogen receptor positive breast cancer | estrogen-receptor positive breast cancer | 179 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000774/ScoringFiles/PGS000774.txt.gz |
PGS000775 (PRS179_ERneg) |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Estrogen receptor negative breast cancer | estrogen-receptor negative breast cancer | 179 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000775/ScoringFiles/PGS000775.txt.gz |
PGS000783 (CC_Breast_IV) |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Breast cancer | breast carcinoma | 162 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000783/ScoringFiles/PGS000783.txt.gz |
PGS000873 (SNP143) |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Breast cancer | breast carcinoma | 143 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000873/ScoringFiles/PGS000873.txt.gz |
PGS001336 (GBE_cancer1002) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Breast cancer | breast carcinoma | 555 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001336/ScoringFiles/PGS001336.txt.gz |
PGS001778 (PRS15_BC) |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Breast cancer | breast carcinoma | 15 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001778/ScoringFiles/PGS001778.txt.gz | |
PGS001804 (portability-PLR_174.1) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Breast cancer (female) | breast carcinoma | 2,984 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001804/ScoringFiles/PGS001804.txt.gz |
PGS002015 (portability-ldpred2_174.1) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Breast cancer (female) | breast carcinoma | 488,608 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002015/ScoringFiles/PGS002015.txt.gz |
PGS002242 (ldpred_breastcancer) |
PGP000271 | Mars N et al. Cell Genom (2022) |
Breast cancer | breast carcinoma | 6,494,889 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002242/ScoringFiles/PGS002242.txt.gz | |
PGS002294 (PRS111) |
PGP000324 | Yang Y et al. JAMA Netw Open (2022) |
Breast cancer | breast carcinoma | 111 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002294/ScoringFiles/PGS002294.txt.gz | |
PGS003380 (best_BRCA) |
PGP000413 | Namba S et al. Cancer Res (2022) |
Breast cancer | breast carcinoma | 1,142,637 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003380/ScoringFiles/PGS003380.txt.gz |
PGS003396 (PRS-11ASN) |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Breast cancer | breast carcinoma | 11 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003396/ScoringFiles/PGS003396.txt.gz |
PGS003397 (PRS-42ASN) |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Breast cancer | breast carcinoma | 42 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003397/ScoringFiles/PGS003397.txt.gz |
PGS003398 (PRS-136EUR) |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Breast cancer | breast carcinoma | 136 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003398/ScoringFiles/PGS003398.txt.gz |
PGS003399 (PRS-209EUR) |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Breast cancer | breast carcinoma | 209 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003399/ScoringFiles/PGS003399.txt.gz |
PGS003738 (PRS136_BC) |
PGP000470 | Xin J et al. EBioMedicine (2023) |
Breast cancer | breast carcinoma | 136 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003738/ScoringFiles/PGS003738.txt.gz | |
PGS003758 (BrCa_PRS_JPHC_JPGWAS) |
PGP000478 | Ohbe H et al. Breast Cancer Res Treat (2022) |
Breast cancer | breast carcinoma | 46,861 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003758/ScoringFiles/PGS003758.txt.gz | |
PGS003759 (BrCa_PRS_JPHC_EURGWAS) |
PGP000478 | Ohbe H et al. Breast Cancer Res Treat (2022) |
Breast cancer | breast carcinoma | 17,252 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003759/ScoringFiles/PGS003759.txt.gz | |
PGS003983 (dbslmm.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 1,137,459 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003983/ScoringFiles/PGS003983.txt.gz | |
PGS003999 (lassosum.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 13,086 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003999/ScoringFiles/PGS003999.txt.gz | |
PGS004025 (ldpred2.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 1,041,298 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004025/ScoringFiles/PGS004025.txt.gz | |
PGS004040 (ldpred2.CV.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 1,041,298 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004040/ScoringFiles/PGS004040.txt.gz | |
PGS004053 (megaprs.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 869,407 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004053/ScoringFiles/PGS004053.txt.gz | |
PGS004069 (megaprs.CV.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 869,407 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004069/ScoringFiles/PGS004069.txt.gz | |
PGS004083 (prscs.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 1,103,877 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004083/ScoringFiles/PGS004083.txt.gz | |
PGS004107 (pt_clump.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 209 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004107/ScoringFiles/PGS004107.txt.gz | |
PGS004123 (pt_clump_nested.CV.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 982 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004123/ScoringFiles/PGS004123.txt.gz | |
PGS004137 (sbayesr.auto.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 950,524 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004137/ScoringFiles/PGS004137.txt.gz | |
PGS004153 (UKBB_EnsPGS.GCST004988.Breast_cancer) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Breast cancer | breast carcinoma | 1,133,268 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004153/ScoringFiles/PGS004153.txt.gz | |
PGS004166 (bc_1) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 3,920 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004166/ScoringFiles/PGS004166.txt.gz |
PGS004167 (bc_2) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 717 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004167/ScoringFiles/PGS004167.txt.gz |
PGS004168 (bc_3) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 4,618 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004168/ScoringFiles/PGS004168.txt.gz |
PGS004169 (bc_4) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 1,361 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004169/ScoringFiles/PGS004169.txt.gz |
PGS004170 (bc_5) |
PGP000520 | Raben TG et al. Sci Rep (2023) |
Breast cancer | breast carcinoma | 2,278 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004170/ScoringFiles/PGS004170.txt.gz |
PGS004242 (PRS306_breast) |
PGP000542 | Kim ES et al. NPJ Precis Oncol (2023) |
Breast cancer | breast carcinoma | 306 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004242/ScoringFiles/PGS004242.txt.gz |
PGS004295 (GenoBoost_breast_cancer_0) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Breast cancer | breast carcinoma | 140 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004295/ScoringFiles/PGS004295.txt.gz |
PGS004296 (GenoBoost_breast_cancer_1) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Breast cancer | breast carcinoma | 80 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004296/ScoringFiles/PGS004296.txt.gz |
PGS004297 (GenoBoost_breast_cancer_2) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Breast cancer | breast carcinoma | 90 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004297/ScoringFiles/PGS004297.txt.gz |
PGS004298 (GenoBoost_breast_cancer_3) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Breast cancer | breast carcinoma | 900 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004298/ScoringFiles/PGS004298.txt.gz |
PGS004299 (GenoBoost_breast_cancer_4) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Breast cancer | breast carcinoma | 70 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004299/ScoringFiles/PGS004299.txt.gz |
PGS004441 (disease.breast_cancer.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
Breast cancer | breast carcinoma | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004441/ScoringFiles/PGS004441.txt.gz |
PGS004511 (meta.breast_cancer.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
Breast cancer | breast carcinoma | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004511/ScoringFiles/PGS004511.txt.gz |
PGS004579 (BRCA_PRSCS) |
PGP000562 | Youssef O et al. Lab Invest (2024) |
Breast cancer | breast carcinoma | 1,088,163 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004579/ScoringFiles/PGS004579.txt.gz |
PGS004611 (RORP_PRS) |
PGP000590 | Shieh Y et al. NPJ Precis Oncol (2023) |
Breast cancer | breast carcinoma | 76 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004611/ScoringFiles/PGS004611.txt.gz | |
PGS004688 (breast_cancer) |
PGP000596 | Hu J et al. JNCI Cancer Spectr (2024) |
Breast cancer | breast carcinoma | 1,044,110 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004688/ScoringFiles/PGS004688.txt.gz | |
PGS004737 (breast_cancer_PRSmix_eur) |
PGP000604 | Truong B et al. Cell Genom (2024) |
Breast cancer | breast carcinoma | 3,666,245 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004737/ScoringFiles/PGS004737.txt.gz |
PGS004738 (breast_cancer_PRSmixPlus_eur) |
PGP000604 | Truong B et al. Cell Genom (2024) |
Breast cancer | breast carcinoma | 3,666,321 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004738/ScoringFiles/PGS004738.txt.gz |
PGS004865 (PRS105_BC) |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
Breast cancer | breast carcinoma | 105 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004865/ScoringFiles/PGS004865.txt.gz |
PGS004866 (PRS105_ERposBC) |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
ER-positive breast cancer | estrogen-receptor positive breast cancer | 105 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004866/ScoringFiles/PGS004866.txt.gz |
PGS004867 (PRS105_ERnegBC) |
PGP000612 | Gao C et al. J Clin Oncol (2021) |
ER-negative breast cancer | estrogen-receptor negative breast cancer | 105 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004867/ScoringFiles/PGS004867.txt.gz |
PGS004869 (INTERVENE_MegaPRS_breast_cancer) |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Breast cancer | breast carcinoma | 872,060 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004869/ScoringFiles/PGS004869.txt.gz | |
PGS004890 (CC-GWAS_PRS) |
PGP000620 | Sun X et al. Cancer Res (2024) |
Triple negative breast cancer versus luminal breast cancer | triple-negative breast cancer | 25 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004890/ScoringFiles/PGS004890.txt.gz |
PGS004891 (TNBC_PRS25) |
PGP000620 | Sun X et al. Cancer Res (2024) |
Triple negative breast cancer | triple-negative breast cancer | 25 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004891/ScoringFiles/PGS004891.txt.gz |
PGS004892 (TNBC_PRS41) |
PGP000620 | Sun X et al. Cancer Res (2024) |
Triple negative breast cancer | triple-negative breast cancer | 41 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004892/ScoringFiles/PGS004892.txt.gz |
PGS004893 (overall.hybrid.prs) |
PGP000621 | Gao G et al. Hum Mol Genet (2022) |
Breast cancer | breast carcinoma | 56,943 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004893/ScoringFiles/PGS004893.txt.gz |
PGS004894 (ERpos.prs) |
PGP000621 | Gao G et al. Hum Mol Genet (2022) |
Estrogen receptor positive breast cancer | estrogen-receptor positive breast cancer | 29,309 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004894/ScoringFiles/PGS004894.txt.gz |
PGS004895 (ERneg.prs) |
PGP000621 | Gao G et al. Hum Mol Genet (2022) |
Estrogen receptor negative breast cancer | estrogen-receptor negative breast cancer | 28,405 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004895/ScoringFiles/PGS004895.txt.gz |
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM000005 | PGS000004 (PRS313_BC) |
PSS000007| European Ancestry| 190,040 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: Incident breast cancer cases | HR: 1.59 [1.54, 1.64] | — | — | study, genetic PCs 1-15 | Included only 306 of the 313 SNPs |
PPM016283 | PGS003399 (PRS-209EUR) |
PSS010095| East Asian Ancestry| 41,031 individuals |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Reported Trait: Occurrence of breast cancer | HR: 1.54 [1.43, 1.66] | AUROC: 0.62 [0.6, 0.64] | — | principal component | — |
PPM000004 | PGS000004 (PRS313_BC) |
PSS000004| European Ancestry| 29,751 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: Invasive breast cancer | OR: 1.61 [1.57, 1.65] | AUROC: 0.63 | — | study, genetic PCs 1-15 | — |
PPM000006 | PGS000005 (PRS313_ERpos) |
PSS000005| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: ER-positive breast cancer | OR: 1.68 [1.63, 1.73] | AUROC: 0.641 | — | study, genetic PCs 1-15 | — |
PPM000007 | PGS000006 (PRS313_ERneg) |
PSS000006| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: ER-negative breast cancer | OR: 1.45 [1.37, 1.53] | AUROC: 0.601 | — | study, genetic PCs 1-15 | — |
PPM000008 | PGS000007 (PRS3820_BC) |
PSS000004| European Ancestry| 29,751 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: Invasive breast cancer | OR: 1.66 [1.61, 1.7] | AUROC: 0.636 | — | study, genetic PCs 1-15 | — |
PPM000009 | PGS000008 (PRS3820_ERpos) |
PSS000005| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: ER-positive breast cancer | OR: 1.73 [1.68, 1.78] | AUROC: 0.647 | — | study, genetic PCs 1-15 | — |
PPM000010 | PGS000009 (PRS3820_ERneg) |
PSS000006| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |
Reported Trait: ER-negative breast cancer | OR: 1.44 [1.36, 1.53] | AUROC: 0.6 | — | study, genetic PCs 1-15 | — |
PPM000011 | PGS000001 (PRS77_BC) |
PSS000004| European Ancestry| 29,751 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |Ext. |
Reported Trait: Invasive breast cancer | OR: 1.46 [1.42, 1.49] | AUROC: 0.603 | — | study, genetic PCs 1-15 | — |
PPM000012 | PGS000002 (PRS77_ERpos) |
PSS000005| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |Ext. |
Reported Trait: ER-positive breast cancer | OR: 1.52 [1.48, 1.56] | AUROC: 0.615 | — | study, genetic PCs 1-15 | — |
PPM000013 | PGS000003 (PRS77_ERneg) |
PSS000006| European Ancestry| 11,428 individuals |
PGP000002 | Mavaddat N et al. Am J Hum Genet (2018) |Ext. |
Reported Trait: ER-negative breast cancer | OR: 1.35 [1.27, 1.43] | AUROC: 0.584 | — | study, genetic PCs 1-15 | — |
PPM000056 | PGS000028 (PRS) |
PSS000040| Multi-ancestry (including European)| 981 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.65 [0.61, 0.68] | — | BCSC risk model | BCSC risk model includes mammographic breast density, age, ethnicity, first-degree relative with breast cancer, and history of breast biopsy |
PPM000058 | PGS000029 (PRS_AS) |
PSS000038| East Asian Ancestry| 102 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.72 [0.62, 0.82] | — | BCSC risk model | BCSC risk model includes mammographic breast density, age, ethnicity, first-degree relative with breast cancer, and history of breast biopsy |
PPM000055 | PGS000028 (PRS) |
PSS000040| Multi-ancestry (including European)| 981 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.6 [0.57, 0.64] | — | — | — |
PPM000120 | PGS000045 (BCPRS_Overall) |
PSS000074| European Ancestry| 1,590 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |Ext. |
Reported Trait: Breast cancer in male carriers of BRCA1/2 mutations | OR: 1.36 [1.19, 1.56] | AUROC: 0.59 [0.55, 0.63] | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | PGS predicting Male Breast Cancer are based on association statistics from a Female Breast Cancer GWAS |
PPM000121 | PGS000046 (BCPRS_ER+) |
PSS000074| European Ancestry| 1,590 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |Ext. |
Reported Trait: Breast cancer in male carriers of BRCA1/2 mutations | OR: 1.36 [1.19, 1.56] | AUROC: 0.59 [0.55, 0.63] | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | PGS predicting Male Breast Cancer are based on association statistics from a Female Breast Cancer GWAS |
PPM000122 | PGS000047 (BCPRS_ER-) |
PSS000074| European Ancestry| 1,590 individuals |
PGP000034 | Lecarpentier J et al. J Clin Oncol (2017) |Ext. |
Reported Trait: Breast cancer in male carriers of BRCA1/2 mutations | OR: 1.19 [1.05, 1.35] | AUROC: 0.55 [0.51, 0.59] | — | 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2 | PGS predicting Male Breast Cancer are based on association statistics from a Female Breast Cancer GWAS |
PPM000126 | PGS000050 (PRS44) |
PSS000078| East Asian Ancestry| 23,567 individuals |
PGP000035 | Wen W et al. Breast Cancer Res (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.606 | Odds Ratio (OR; per decile of PRS): 1.13 [1.12, 1.14] | NR | Potentially overfit: samples were used to select the variants included in the PRS (see paper's Discussion section for more information). |
PPM000127 | PGS000050 (PRS44) |
PSS000079| East Asian Ancestry| 5,152 individuals |
PGP000035 | Wen W et al. Breast Cancer Res (2016) |
Reported Trait: Breast cancer | — | C-index: 0.602 | C-index improvement (with PRS): 0.0386 [0.0259, 0.0513] | age at menarche, age at first live birth, waist-to-hip ratio, breast cancer family history, prior benign breast disease | Potentially overfit: samples were used to select the variants included in the PRS (see paper's Discussion section for more information). |
PPM000128 | PGS000051 (PRS67) |
PSS000080| Multi-ancestry (including European)| 11,880 individuals |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Reported Trait: Invasive breast cancer | — | AUROC: 0.65 [0.64, 0.66] | — | Gail BC risk model, Mammographic density (MD), Testoterone (T), estrone sulfate (E1S), prolactin (PRL) | Age-adjusted AUC |
PPM013022 | PGS002294 (PRS111) |
PSS009652| East Asian Ancestry| 1,104 individuals |
PGP000324 | Yang Y et al. JAMA Netw Open (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.648 [0.613, 0.682] | — | Nongenetic risk score (body mass index, waist-to-hip ratio (WHR), benign breast disease, age at menarche, age at first live birth, family history of breast cancer) | — |
PPM000940 | PGS000004 (PRS313_BC) |
PSS000482| European Ancestry| 84,607 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.39 [1.13, 1.7] | — | — | Age, country, PCs (1-10) | — |
PPM000106 | PGS000045 (BCPRS_Overall) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.14 [1.11, 1.17] | C-index: 0.541 [0.53, 0.551] | — | Country, birth year | — |
PPM000107 | PGS000045 (BCPRS_Overall) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.22 [1.17, 1.28] | C-index: 0.566 [0.551, 0.581] | — | Country, birth year | — |
PPM000108 | PGS000046 (BCPRS_ER+) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.11 [1.08, 1.15] | C-index: 0.532 [0.522, 0.543] | — | Country, birth year | — |
PPM000109 | PGS000046 (BCPRS_ER+) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.22 [1.16, 1.27] | C-index: 0.566 [0.551, 0.581] | — | Country, birth year | — |
PPM000938 | PGS000004 (PRS313_BC) |
PSS000482| European Ancestry| 84,607 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.3 [1.26, 1.35] | — | — | Age, country | — |
PPM000192 | PGS000072 (CC_Breast) |
PSS000111| European Ancestry| 237,549 individuals |
PGP000050 | Graff RE et al. Nat Commun (2021) |
Reported Trait: Breast cancer | OR: 1.26 [1.24, 1.28] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. | Results from meta-analysis of GERA and UKB |
PPM000002 | PGS000002 (PRS77_ERpos) |
PSS000003| European Ancestry| 53,923 individuals |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
Reported Trait: ER-positive breast cancer | OR: 1.63 [1.6, 1.67] | — | — | — | — |
PPM000130 | PGS000051 (PRS67) |
PSS000080| Multi-ancestry (including European)| 11,880 individuals |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Reported Trait: Invasive breast cancer | — | — | Relative Risk (RR; higest vs. lowest quartile PRS): 2.5 [2.2, 2.8] | Demographics and parameters of baseline blood draw (age, BMI, fasting status, time of day, season), history of benign breast disease, family history of breast cancer, age at menopause, age at menarche, physical activity, age at first birth and parity | — |
PPM000060 | PGS000028 (PRS) |
PSS000039| European Ancestry| 774 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.63 [0.59, 0.67] | — | — | — |
PPM000386 | PGS000007 (PRS3820_BC) |
PSS000218| European Ancestry| 9,529 individuals |
PGP000057 | Homburger JR et al. Genome Med (2019) |Ext. |
Reported Trait: Breast Cancer (personal history) | — | AUROC: 0.78 | — | age, sex | — |
PPM001345 | PGS000004 (PRS313_BC) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer | HR: 1.55 [1.52, 1.58] | — | — | 10 ancestry PCs, batch, age as time scale | 260/313 variants in the PRS are polymorphic in FinnGen |
PPM000024 | PGS000015 (GPS_BC) |
PSS000014| European Ancestry| 157,895 individuals |
PGP000006 | Khera AV et al. Nat Genet (2018) |
Reported Trait: Breast cancer | — | AUROC: 0.69 [0.68, 0.69] | Nagelkerke’s R2 (estimate of variance explained by the PGS after covariate adjustment): 0.027 | age; sex; Ancestry PC 1-4; genotyping chip | — |
PPM000110 | PGS000047 (BCPRS_ER-) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.27 [1.23, 1.31] | C-index: 0.581 [0.571, 0.592] | — | Country, birth year | — |
PPM000111 | PGS000047 (BCPRS_ER-) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.15 [1.1, 1.2] | C-index: 0.538 [0.523, 0.553] | — | Country, birth year | — |
PPM000114 | PGS000001 (PRS77_BC) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.13 [1.1, 1.16] | — | — | Country, birth year | — |
PPM000115 | PGS000002 (PRS77_ERpos) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.09 [1.06, 1.12] | — | — | Country, birth year | — |
PPM000116 | PGS000003 (PRS77_ERneg) |
PSS000070| European Ancestry| 15,252 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA1 mutation carriers | HR: 1.24 [1.21, 1.28] | — | — | Country, birth year | — |
PPM000117 | PGS000001 (PRS77_BC) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.22 [1.17, 1.28] | — | — | Country, birth year | — |
PPM000118 | PGS000002 (PRS77_ERpos) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.22 [1.17, 1.27] | — | — | Country, birth year | — |
PPM000119 | PGS000003 (PRS77_ERneg) |
PSS000071| European Ancestry| 8,211 individuals |
PGP000033 | Kuchenbaecker KB et al. J Natl Cancer Inst (2017) |Ext. |
Reported Trait: Breast cancer in BRCA2 mutation carriers | HR: 1.13 [1.08, 1.18] | — | — | Country, birth year | — |
PPM000131 | PGS000052 (sPRS161) |
PSS000082| European Ancestry| 585 individuals |
PGP000037 | Lakeman IMM et al. J Med Genet (2019) |
Reported Trait: breast cancer | HR: 1.16 [1.03, 1.28] | — | — | family history (estimated using the BOADICEA risk model) | — |
PPM000384 | PGS000007 (PRS3820_BC) |
PSS000218| European Ancestry| 9,529 individuals |
PGP000057 | Homburger JR et al. Genome Med (2019) |Ext. |
Reported Trait: Breast Cancer (personal history) | OR: 1.56 [1.45, 1.68] | — | — | age at menarche | — |
PPM000059 | PGS000028 (PRS) |
PSS000038| East Asian Ancestry| 102 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.62 [0.52, 0.73] | — | — | — |
PPM000899 | PGS000332 (PRS_BC) |
PSS000444| European Ancestry| 37,841 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident breast cancer | — | C-index: 0.75 | — | age, family history of breast cancer, current smoking, BMI, alcohol use disorder, years of hormone replacement therapy, having given birth to one or more children, genotyping array/batch, 10 ancestry PCs | 10-year risk |
PPM000894 | PGS000332 (PRS_BC) |
PSS000444| European Ancestry| 37,841 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Incident breast cancer | — | C-index: 0.737 | — | age, genotyping array/batch, 10 ancestry PCs | 10-year risk |
PPM000001 | PGS000001 (PRS77_BC) |
PSS000001| European Ancestry| 67,054 individuals |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
Reported Trait: All breast cancer | OR: 1.55 [1.52, 1.58] | C-index: 0.622 [0.619, 0.627] | — | — | — |
PPM000003 | PGS000003 (PRS77_ERneg) |
PSS000002| European Ancestry| 38,722 individuals |
PGP000001 | Mavaddat N et al. J Natl Cancer Inst (2015) |
Reported Trait: ER-negative breast cancer | OR: 1.45 [1.4, 1.49] | — | — | — | — |
PPM000057 | PGS000029 (PRS_AS) |
PSS000038| East Asian Ancestry| 102 individuals |
PGP000018 | Shieh Y et al. Breast Cancer Res Treat (2016) |
Reported Trait: Breast cancer | — | AUROC: 0.64 [0.53, 0.74] | — | — | — |
PPM000388 | PGS000007 (PRS3820_BC) |
PSS000218| European Ancestry| 9,529 individuals |
PGP000057 | Homburger JR et al. Genome Med (2019) |Ext. |
Reported Trait: Breast Cancer (personal history) | — | AUROC: 0.63 | — | — | — |
PPM000484 | PGS000153 (cGRS_Breast) |
PSS000273| European Ancestry| 7,847 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Breast cancer | — | — | Odds Ratio (OR; high vs. average risk groups): 1.47 [1.23, 1.76] | — | — |
PPM000473 | PGS000153 (cGRS_Breast) |
PSS000273| European Ancestry| 7,847 individuals |
PGP000075 | Shi Z et al. Cancer Med (2019) |
Reported Trait: Breast cancer | — | — | Mean realative risk: 1.15 [1.11, 1.2] Wilcoxon test (case vs. control) p-value: 1.48e-14 |
— | — |
PPM000964 | PGS000005 (PRS313_ERpos) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.22 [1.15, 1.3] | — | — | Country | — |
PPM000963 | PGS000005 (PRS313_ERpos) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.23 [1.16, 1.31] | — | — | Country | — |
PPM000962 | PGS000001 (PRS77_BC) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.21 [1.13, 1.29] | — | — | Country | — |
PPM000947 | PGS000005 (PRS313_ERpos) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.22 [1.15, 1.3] | — | — | Country | — |
PPM000946 | PGS000005 (PRS313_ERpos) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.23 [1.16, 1.31] | — | — | Country | — |
PPM000945 | PGS000001 (PRS77_BC) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.21 [1.13, 1.29] | — | — | Country | — |
PPM000944 | PGS000001 (PRS77_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.21 [1.14, 1.29] | — | — | Country | — |
PPM000941 | PGS000004 (PRS313_BC) |
PSS000483| European Ancestry| 143,830 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.67 [1.59, 1.76] | — | — | Age, country, PCs (1-10) | — |
PPM000957 | PGS000004 (PRS313_BC) |
PSS000482| European Ancestry| 84,607 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.39 [1.13, 1.7] | — | — | Age, country, PCs (1-10) | — |
PPM000959 | PGS000004 (PRS313_BC) |
PSS000481| Additional Asian Ancestries| 12,473 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.15 [1.02, 1.29] | — | — | Age, country | — |
PPM000955 | PGS000004 (PRS313_BC) |
PSS000482| European Ancestry| 84,607 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.3 [1.26, 1.35] | — | — | Age, country | — |
PPM001347 | PGS000004 (PRS313_BC) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer | OR: 1.61 [1.57, 1.64] | — | — | Age, 10 ancestry PCs, batch | 260/313 variants in the PRS are polymorphic in FinnGen |
PPM000965 | PGS000005 (PRS313_ERpos) |
PSS000485| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Estrogen-receptor positive metachronous invasive contralateral breast cancer | HR: 1.37 [1.22, 1.54] | — | — | Country | — |
PPM000961 | PGS000001 (PRS77_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.21 [1.14, 1.29] | — | — | Country | — |
PPM000958 | PGS000004 (PRS313_BC) |
PSS000483| European Ancestry| 143,830 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.67 [1.59, 1.76] | — | — | Age, country, PCs (1-10) | — |
PPM000954 | PGS000004 (PRS313_BC) |
PSS000485| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Estrogen-receptor positive metachronous invasive contralateral breast cancer | HR: 1.38 [1.23, 1.55] | — | — | Country | — |
PPM000953 | PGS000004 (PRS313_BC) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.24 [1.16, 1.32] | — | — | Country | — |
PPM000951 | PGS000004 (PRS313_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.25 [1.18, 1.33] | C-index: 0.563 [0.547, 0.586] | — | Country | — |
PPM000950 | PGS000006 (PRS313_ERneg) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.24 [1.16, 1.33] | — | — | Country | — |
PPM000949 | PGS000006 (PRS313_ERneg) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.25 [1.17, 1.33] | — | — | Country | — |
PPM000948 | PGS000005 (PRS313_ERpos) |
PSS000485| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Estrogen-receptor positive metachronous invasive contralateral breast cancer | HR: 1.37 [1.22, 1.54] | — | — | Country | — |
PPM000942 | PGS000004 (PRS313_BC) |
PSS000481| Additional Asian Ancestries| 12,473 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Contralateral breast cancer | OR: 1.15 [1.02, 1.29] | — | — | Age, country | — |
PPM000960 | PGS000004 (PRS313_BC) |
PSS000480| Additional Asian Ancestries| 25,531 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.56 [1.52, 1.6] | — | — | Age, country | — |
PPM000956 | PGS000004 (PRS313_BC) |
PSS000483| European Ancestry| 143,830 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.82 [1.8, 1.84] | — | — | Age, country | — |
PPM000943 | PGS000004 (PRS313_BC) |
PSS000480| Additional Asian Ancestries| 25,531 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.56 [1.52, 1.6] | — | — | Age, country | — |
PPM000937 | PGS000004 (PRS313_BC) |
PSS000485| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Estrogen-receptor positive metachronous invasive contralateral breast cancer | HR: 1.38 [1.23, 1.55] | — | — | Country | — |
PPM000936 | PGS000004 (PRS313_BC) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.24 [1.16, 1.32] | — | — | Country | — |
PPM000935 | PGS000004 (PRS313_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | — | C-index: 0.623 [0.591, 0.629] | — | Country, age at first diagnosis, year of first diagnosis, family history for breast cancer in a first degree relative, clinical characteristics of the first breast cancer (nodal status, tumor size, differentiation grade, morphology, estrogen receptor status, human epidermal growth factor receptor 2 status, chemotherapy, endocrine therapy, radiotherapy) | — |
PPM000934 | PGS000004 (PRS313_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.25 [1.18, 1.33] | C-index: 0.563 [0.547, 0.586] | — | Country | — |
PPM000967 | PGS000006 (PRS313_ERneg) |
PSS000486| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Invasive metachronous contralateral breast cancer | HR: 1.24 [1.16, 1.33] | — | — | Country | — |
PPM000966 | PGS000006 (PRS313_ERneg) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | HR: 1.25 [1.17, 1.33] | — | — | Country | — |
PPM000952 | PGS000004 (PRS313_BC) |
PSS000484| European Ancestry| 56,068 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Metachronous contralateral breast cancer | — | C-index: 0.623 [0.591, 0.629] | — | Country, age at first diagnosis, year of first diagnosis, family history for breast cancer in a first degree relative, clinical characteristics of the first breast cancer (nodal status, tumor size, differentiation grade, morphology, estrogen receptor status, human epidermal growth factor receptor 2 status, chemotherapy, endocrine therapy, radiotherapy) | — |
PPM000983 | PGS000345 (PRS229_BC) |
PSS000491| Additional Asian Ancestries| 32,238 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.49 [1.45, 1.52] | AUROC: 0.611 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
PPM000982 | PGS000345 (PRS229_BC) |
PSS000500| East Asian Ancestry| 10,255 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Incident breast cancer | HR: 1.49 [1.33, 1.67] | C-index: 0.61 | — | PCs (1-7), study, array,batch | Standardised to SDs of PRs in European controls |
PPM000981 | PGS000346 (PRS287_ERneg) |
PSS000498| Additional Asian Ancestries| 1,492 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-negative breast cancer | OR: 1.49 [1.26, 1.75] | AUROC: 0.587 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
PPM000980 | PGS000347 (PRS287_ERpos) |
PSS000499| Additional Asian Ancestries| 2,234 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-positive breast cancer | OR: 1.38 [1.25, 1.53] | AUROC: 0.586 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
PPM000979 | PGS000344 (PRS287_BC) |
PSS000497| Additional Asian Ancestries| 2,719 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.36 [1.25, 1.49] | AUROC: 0.577 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
PPM000978 | PGS000346 (PRS287_ERneg) |
PSS000495| Multi-ancestry (excluding European)| 9,391 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-negative breast cancer | OR: 1.43 [1.35, 1.52] | — | — | PCs (1-10), study, array,batch | — |
PPM000977 | PGS000347 (PRS287_ERpos) |
PSS000496| Multi-ancestry (excluding European)| 12,222 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-positive breast cancer | OR: 1.59 [1.53, 1.66] | — | — | PCs (1-10), study, array,batch | — |
PPM000976 | PGS000344 (PRS287_BC) |
PSS000494| Multi-ancestry (excluding European)| 14,406 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.55 [1.5, 1.61] | — | — | PCs (1-10), study, array,batch | — |
PPM000974 | PGS000347 (PRS287_ERpos) |
PSS000492| Additional Asian Ancestries| 26,960 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-positive breast cancer | OR: 1.62 [1.57, 1.67] | AUROC: 0.627 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
PPM000973 | PGS000344 (PRS287_BC) |
PSS000491| Additional Asian Ancestries| 32,238 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.52 [1.49, 1.56] | AUROC: 0.613 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
PPM000939 | PGS000004 (PRS313_BC) |
PSS000483| European Ancestry| 143,830 individuals |
PGP000109 | Kramer I et al. Am J Hum Genet (2020) |Ext. |
Reported Trait: Unilateral breast cancer | OR: 1.82 [1.8, 1.84] | — | — | Age, country | — |
PPM001205 | PGS000520 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.188 [1.158, 1.22] β: 0.172 (0.0133) |
AUROC: 0.549 [0.542, 0.556] | Nagelkerke's Pseudo-R²: 0.00537 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.82 [1.48, 2.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608 |
PPM001206 | PGS000521 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.22 [1.149, 1.295] β: 0.199 (0.0304) |
AUROC: 0.548 [0.53, 0.564] | Nagelkerke's Pseudo-R²: 0.00934 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.88 [1.18, 2.99] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_MGI_20200608 |
PPM001208 | PGS000523 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.225 [1.155, 1.299] β: 0.203 (0.0301) |
AUROC: 0.546 [0.529, 0.562] | Nagelkerke's Pseudo-R²: 0.00979 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 2.11 [1.34, 3.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608 |
PPM001209 | PGS000524 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.2 [1.169, 1.231] β: 0.182 (0.0131) |
AUROC: 0.547 [0.54, 0.555] | Nagelkerke's Pseudo-R²: 0.0061 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.72 [1.4, 2.11] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608 |
PPM001211 | PGS000526 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.424 [1.387, 1.461] β: 0.353 (0.0132) |
AUROC: 0.597 [0.59, 0.604] | Nagelkerke's Pseudo-R²: 0.0228 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 2.68 [2.25, 3.19] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608 |
PPM001212 | PGS000527 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.509 [1.418, 1.605] β: 0.411 (0.0314) |
AUROC: 0.613 [0.595, 0.63] | Nagelkerke's Pseudo-R²: 0.0383 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.75 [2.55, 5.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608 |
PPM001214 | PGS000529 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.43 [1.346, 1.52] β: 0.358 (0.0311) |
AUROC: 0.597 [0.58, 0.612] | Nagelkerke's Pseudo-R²: 0.0281 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.98 [1.98, 4.47] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_MGI_20200608 |
PPM001012 | PGS000004 (PRS313_BC) |
PSS000521| European Ancestry| 18,935 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA1 carriers | HR: 1.2 [1.17, 1.23] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001013 | PGS000004 (PRS313_BC) |
PSS000525| European Ancestry| 12,339 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA2 carriers | HR: 1.31 [1.26, 1.36] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001014 | PGS000004 (PRS313_BC) |
PSS000522| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA1 carriers | HR: 1.09 [1.05, 1.13] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001015 | PGS000004 (PRS313_BC) |
PSS000526| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA2 carriers | HR: 1.19 [1.1, 1.29] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001016 | PGS000004 (PRS313_BC) |
PSS000523| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA1 carriers | HR: 1.44 [1.35, 1.54] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001017 | PGS000004 (PRS313_BC) |
PSS000527| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA2 carriers | HR: 1.36 [1.3, 1.43] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001018 | PGS000005 (PRS313_ERpos) |
PSS000521| European Ancestry| 18,935 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA1 carriers | HR: 1.17 [1.14, 1.2] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001019 | PGS000005 (PRS313_ERpos) |
PSS000525| European Ancestry| 12,339 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA2 carriers | HR: 1.3 [1.26, 1.35] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001020 | PGS000005 (PRS313_ERpos) |
PSS000522| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA1 carriers | HR: 1.06 [1.02, 1.1] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001021 | PGS000005 (PRS313_ERpos) |
PSS000526| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA2 carriers | HR: 1.15 [1.07, 1.25] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001022 | PGS000005 (PRS313_ERpos) |
PSS000523| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA1 carriers | HR: 1.45 [1.35, 1.54] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001023 | PGS000005 (PRS313_ERpos) |
PSS000527| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA2 carriers | HR: 1.37 [1.31, 1.44] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001024 | PGS000006 (PRS313_ERneg) |
PSS000521| European Ancestry| 18,935 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA1 carriers | HR: 1.29 [1.25, 1.33] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001025 | PGS000006 (PRS313_ERneg) |
PSS000525| European Ancestry| 12,339 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Breast cancer in BRCA2 carriers | HR: 1.23 [1.18, 1.27] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001026 | PGS000006 (PRS313_ERneg) |
PSS000522| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA1 carriers | HR: 1.23 [1.18, 1.27] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001027 | PGS000006 (PRS313_ERneg) |
PSS000526| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER negative breast cancer in BRCA2 carriers | HR: 1.29 [1.19, 1.41] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001028 | PGS000006 (PRS313_ERneg) |
PSS000523| European Ancestry| 13,401 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA1 carriers | HR: 1.29 [1.21, 1.37] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001029 | PGS000006 (PRS313_ERneg) |
PSS000527| European Ancestry| 8,752 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: ER positive breast cancer in BRCA2 carriers | HR: 1.21 [1.15, 1.27] | — | — | birth cohort, PCs(1-4) of ancestry, family history in first- and second-degree relatives | — |
PPM001034 | PGS000006 (PRS313_ERneg) |
PSS000529| European Ancestry| 2,088 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Incident breast cancer in BRCA1 carriers | HR: 1.28 [1.14, 1.44] | — | — | family history of the appropriate cancer in first- and second-degree relatives | — |
PPM001035 | PGS000004 (PRS313_BC) |
PSS000531| European Ancestry| 1,757 individuals |
PGP000117 | Barnes DR et al. Genet Med (2020) |Ext. |
Reported Trait: Incidient breast cancer in BRCA2 carriers | HR: 1.36 [1.17, 1.57] | — | — | family history of the appropriate cancer in first- and second-degree relatives | — |
PPM001157 | PGS000472 (PRSWEB_PHECODE174.1_20001-1002_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.343 [1.266, 1.426] β: 0.295 (0.0303) |
AUROC: 0.579 [0.561, 0.597] | Nagelkerke's Pseudo-R²: 0.0204 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 2.32 [1.49, 3.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_P_5e-08_MGI_20200608 |
PPM001160 | PGS000475 (PRSWEB_PHECODE174.1_20001-1002_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.349 [1.269, 1.434] β: 0.299 (0.0312) |
AUROC: 0.586 [0.57, 0.603] | Nagelkerke's Pseudo-R²: 0.0196 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.59 [0.962, 2.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_LASSOSUM_MGI_20200608 |
PPM001163 | PGS000478 (PRSWEB_PHECODE174.1_C3-BREAST-3_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.411 [1.328, 1.5] β: 0.344 (0.031) |
AUROC: 0.595 [0.578, 0.611] | Nagelkerke's Pseudo-R²: 0.0257 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.31 [1.47, 3.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_PT_MGI_20200608 |
PPM001166 | PGS000481 (PRSWEB_PHECODE174.1_C50_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.323 [1.246, 1.406] β: 0.28 (0.0307) |
AUROC: 0.578 [0.56, 0.596] | Nagelkerke's Pseudo-R²: 0.0183 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 2.03 [1.29, 3.2] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_PRS-CS_MGI_20200608 |
PPM001169 | PGS000484 (PRSWEB_PHECODE174.1_D05_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.12 [1.056, 1.187] β: 0.113 (0.0297) |
AUROC: 0.52 [0.504, 0.538] | Nagelkerke's Pseudo-R²: 0.00286 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.39 [0.817, 2.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_D05_PT_MGI_20200608 |
PPM001172 | PGS000487 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.488 [1.399, 1.582] β: 0.397 (0.0313) |
AUROC: 0.607 [0.589, 0.623] | Nagelkerke's Pseudo-R²: 0.0346 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.06 [2.04, 4.6] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_MGI_20200608 |
PPM001175 | PGS000490 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | β: 0.221 (0.0132) OR: 1.248 [1.216, 1.28] |
AUROC: 0.559 [0.551, 0.566] | Nagelkerke's Pseudo-R²: 0.00891 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 2.03 [1.67, 2.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608 |
PPM001178 | PGS000493 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.31 [1.234, 1.391] β: 0.27 (0.0306) |
AUROC: 0.576 [0.559, 0.593] | Nagelkerke's Pseudo-R²: 0.0173 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.84 [1.14, 2.97] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_MGI_20200608 |
PPM001181 | PGS000496 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.323 [1.289, 1.358] β: 0.28 (0.0133) |
AUROC: 0.576 [0.568, 0.583] | Nagelkerke's Pseudo-R²: 0.0141 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 2.25 [1.86, 2.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_UKB_20200608 |
PPM001195 | PGS000510 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.612 [1.57, 1.656] β: 0.478 (0.0136) |
AUROC: 0.63 [0.623, 0.637] | Nagelkerke's Pseudo-R²: 0.0401 Brier score: 0.0811 Odds Ratio (OR, top 1% vs. Rest): 3.32 [2.83, 3.9] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_UKB_20200608 |
PPM001198 | PGS000513 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.402 [1.32, 1.489] β: 0.338 (0.0307) |
AUROC: 0.595 [0.577, 0.612] | Nagelkerke's Pseudo-R²: 0.0259 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.8 [1.12, 2.91] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_P_5e-08_MGI_20200608 |
PPM001201 | PGS000516 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.477 [1.39, 1.57] β: 0.39 (0.031) |
AUROC: 0.609 [0.592, 0.624] | Nagelkerke's Pseudo-R²: 0.034 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.94 [1.21, 3.11] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_LASSOSUM_MGI_20200608 |
PPM001204 | PGS000519 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.151 [1.084, 1.221] β: 0.14 (0.0305) |
AUROC: 0.539 [0.52, 0.556] | Nagelkerke's Pseudo-R²: 0.00453 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.51 [0.907, 2.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608 |
PPM001207 | PGS000522 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.201 [1.171, 1.233] β: 0.183 (0.0131) |
AUROC: 0.547 [0.54, 0.555] | Nagelkerke's Pseudo-R²: 0.00619 Brier score: 0.0825 Odds Ratio (OR, top 1% vs. Rest): 1.73 [1.41, 2.13] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_PT_UKB_20200608 |
PPM001210 | PGS000525 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.427 [1.343, 1.516] β: 0.356 (0.0309) |
AUROC: 0.597 [0.58, 0.614] | Nagelkerke's Pseudo-R²: 0.0285 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.28 [1.46, 3.56] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608 |
PPM001188 | PGS000503 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.656 [1.554, 1.766] β: 0.505 (0.0326) |
AUROC: 0.634 [0.618, 0.65] | Nagelkerke's Pseudo-R²: 0.0546 Brier score: 0.135 Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.78, 5.85] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608 |
PPM001192 | PGS000507 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.772 [1.659, 1.891] β: 0.572 (0.0334) |
AUROC: 0.651 [0.635, 0.666] | Nagelkerke's Pseudo-R²: 0.0661 Brier score: 0.133 Odds Ratio (OR, top 1% vs. Rest): 3.22 [2.15, 4.81] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_MGI_20200608 |
PPM001213 | PGS000528 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.513 [1.474, 1.554] β: 0.414 (0.0136) |
AUROC: 0.614 [0.607, 0.62] | Nagelkerke's Pseudo-R²: 0.0303 Brier score: 0.0816 Odds Ratio (OR, top 1% vs. Rest): 2.98 [2.52, 3.52] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608 |
PPM001216 | PGS000531 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.501 [1.411, 1.596] β: 0.406 (0.0314) |
AUROC: 0.61 [0.594, 0.626] | Nagelkerke's Pseudo-R²: 0.037 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.29 [1.47, 3.59] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_MGI_20200608 |
PPM001219 | PGS000534 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.443 [1.406, 1.481] β: 0.367 (0.0132) |
AUROC: 0.601 [0.594, 0.608] | Nagelkerke's Pseudo-R²: 0.0246 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.5 [2.09, 2.99] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_UKB_20200608 |
PPM001222 | PGS000537 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.498 [1.408, 1.593] β: 0.404 (0.0314) |
AUROC: 0.609 [0.592, 0.626] | Nagelkerke's Pseudo-R²: 0.0353 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.44 [2.31, 5.13] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_MGI_20200608 |
PPM001225 | PGS000540 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.528 [1.489, 1.569] β: 0.424 (0.0134) |
AUROC: 0.615 [0.607, 0.622] | Nagelkerke's Pseudo-R²: 0.0322 Brier score: 0.0814 Odds Ratio (OR, top 1% vs. Rest): 3.55 [3.04, 4.16] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608 |
PPM000984 | PGS000345 (PRS229_BC) |
PSS000497| Additional Asian Ancestries| 2,719 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.33 [1.22, 1.45] | AUROC: 0.579 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
PPM000975 | PGS000346 (PRS287_ERneg) |
PSS000493| Additional Asian Ancestries| 21,247 individuals |
PGP000112 | Ho WK et al. Nat Commun (2020) |
Reported Trait: ER-negative breast cancer | OR: 1.41 [1.36, 1.46] | AUROC: 0.594 | — | PCs (1-10), study, array,batch | Standardised to SDs of PRs in European controls |
PPM001158 | PGS000473 (PRSWEB_PHECODE174.1_20001-1002_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.315 [1.238, 1.398] β: 0.274 (0.0311) |
AUROC: 0.576 [0.56, 0.592] | Nagelkerke's Pseudo-R²: 0.0167 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.6 [0.981, 2.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_PRS-CS_MGI_20200608 |
PPM001159 | PGS000474 (PRSWEB_PHECODE174.1_20001-1002_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.338 [1.26, 1.422] β: 0.291 (0.0308) |
AUROC: 0.58 [0.563, 0.597] | Nagelkerke's Pseudo-R²: 0.0188 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.54 [0.924, 2.56] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_20001-1002_PT_MGI_20200608 |
PPM001161 | PGS000476 (PRSWEB_PHECODE174.1_C3-BREAST-3_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.365 [1.286, 1.45] β: 0.311 (0.0305) |
AUROC: 0.585 [0.569, 0.603] | Nagelkerke's Pseudo-R²: 0.0218 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.97 [1.24, 3.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_P_5e-08_MGI_20200608 |
PPM001162 | PGS000477 (PRSWEB_PHECODE174.1_C3-BREAST-3_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.338 [1.259, 1.421] β: 0.291 (0.0308) |
AUROC: 0.581 [0.564, 0.597] | Nagelkerke's Pseudo-R²: 0.0193 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 2.17 [1.38, 3.41] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_PRS-CS_MGI_20200608 |
PPM001164 | PGS000479 (PRSWEB_PHECODE174.1_C3-BREAST-3_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.438 [1.354, 1.528] β: 0.364 (0.0308) |
AUROC: 0.6 [0.584, 0.616] | Nagelkerke's Pseudo-R²: 0.03 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.37 [1.54, 3.65] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C3-BREAST-3_LASSOSUM_MGI_20200608 |
PPM001167 | PGS000482 (PRSWEB_PHECODE174.1_C50_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.358 [1.279, 1.442] β: 0.306 (0.0306) |
AUROC: 0.584 [0.568, 0.601] | Nagelkerke's Pseudo-R²: 0.0212 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.43 [0.853, 2.41] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_PT_MGI_20200608 |
PPM001168 | PGS000483 (PRSWEB_PHECODE174.1_C50_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.404 [1.322, 1.491] β: 0.339 (0.0308) |
AUROC: 0.595 [0.579, 0.61] | Nagelkerke's Pseudo-R²: 0.0264 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.05 [1.3, 3.24] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_LASSOSUM_MGI_20200608 |
PPM001170 | PGS000485 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.488 [1.399, 1.582] β: 0.397 (0.0313) |
AUROC: 0.607 [0.589, 0.623] | Nagelkerke's Pseudo-R²: 0.0346 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.06 [2.04, 4.6] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_MGI_20200608 |
PPM001171 | PGS000486 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.4 [1.363, 1.437] β: 0.336 (0.0134) |
AUROC: 0.592 [0.585, 0.6] | Nagelkerke's Pseudo-R²: 0.0202 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.58 [2.16, 3.07] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_P_5e-08_UKB_20200608 |
PPM001173 | PGS000488 (PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.426 [1.389, 1.464] β: 0.355 (0.0134) |
AUROC: 0.598 [0.59, 0.605] | Nagelkerke's Pseudo-R²: 0.0226 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 2.68 [2.25, 3.18] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_GWAS-Catalog-r2019-05-03-X174.1_PT_UKB_20200608 |
PPM001174 | PGS000489 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.254 [1.181, 1.33] β: 0.226 (0.0304) |
AUROC: 0.564 [0.547, 0.58] | Nagelkerke's Pseudo-R²: 0.012 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.72 [1.05, 2.81] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608 |
PPM001176 | PGS000491 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.326 [1.246, 1.411] β: 0.282 (0.0317) |
AUROC: 0.578 [0.56, 0.594] | Nagelkerke's Pseudo-R²: 0.0179 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.8 [1.13, 2.88] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_MGI_20200608 |
PPM001177 | PGS000492 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.33 [1.296, 1.366] β: 0.286 (0.0134) |
AUROC: 0.579 [0.572, 0.586] | Nagelkerke's Pseudo-R²: 0.0146 Brier score: 0.0822 Odds Ratio (OR, top 1% vs. Rest): 2.34 [1.95, 2.82] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PRS-CS_UKB_20200608 |
PPM001179 | PGS000494 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.248 [1.216, 1.28] β: 0.221 (0.0132) |
AUROC: 0.559 [0.551, 0.566] | Nagelkerke's Pseudo-R²: 0.00891 Brier score: 0.0824 Odds Ratio (OR, top 1% vs. Rest): 2.03 [1.67, 2.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_PT_UKB_20200608 |
PPM001180 | PGS000495 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.297 [1.221, 1.377] β: 0.26 (0.0307) |
AUROC: 0.571 [0.555, 0.588] | Nagelkerke's Pseudo-R²: 0.0152 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.87 [1.16, 3.01] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-negative-BRCA_LASSOSUM_MGI_20200608 |
PPM001182 | PGS000497 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.521 [1.43, 1.619] β: 0.42 (0.0316) |
AUROC: 0.614 [0.599, 0.63] | Nagelkerke's Pseudo-R²: 0.0383 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.35 [1.51, 3.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_MGI_20200608 |
PPM001183 | PGS000498 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.513 [1.474, 1.553] β: 0.414 (0.0133) |
AUROC: 0.613 [0.606, 0.621] | Nagelkerke's Pseudo-R²: 0.0311 Brier score: 0.0815 Odds Ratio (OR, top 1% vs. Rest): 2.71 [2.28, 3.23] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_P_5e-08_UKB_20200608 |
PPM001184 | PGS000499 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.708 [1.601, 1.822] β: 0.535 (0.033) |
AUROC: 0.643 [0.627, 0.658] | Nagelkerke's Pseudo-R²: 0.0603 Brier score: 0.134 Odds Ratio (OR, top 1% vs. Rest): 3.71 [2.52, 5.47] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_MGI_20200608 |
PPM001186 | PGS000501 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.564 [1.469, 1.665] β: 0.447 (0.0318) |
AUROC: 0.621 [0.605, 0.638] | Nagelkerke's Pseudo-R²: 0.0438 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.7 [1.77, 4.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_MGI_20200608 |
PPM001187 | PGS000502 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.555 [1.514, 1.596] β: 0.441 (0.0135) |
AUROC: 0.621 [0.614, 0.628] | Nagelkerke's Pseudo-R²: 0.0347 Brier score: 0.0814 Odds Ratio (OR, top 1% vs. Rest): 3.36 [2.87, 3.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PT_UKB_20200608 |
PPM001189 | PGS000504 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.621 [1.578, 1.665] β: 0.483 (0.0136) |
AUROC: 0.631 [0.624, 0.638] | Nagelkerke's Pseudo-R²: 0.0408 Brier score: 0.0811 Odds Ratio (OR, top 1% vs. Rest): 3.86 [3.31, 4.5] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608 |
PPM001190 | PGS000505 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.584 [1.488, 1.686] β: 0.46 (0.0318) |
AUROC: 0.625 [0.609, 0.641] | Nagelkerke's Pseudo-R²: 0.0462 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.32 [2.24, 4.93] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_MGI_20200608 |
PPM001215 | PGS000530 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.441 [1.404, 1.479] β: 0.365 (0.0132) |
AUROC: 0.6 [0.593, 0.608] | Nagelkerke's Pseudo-R²: 0.0245 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.92 [2.47, 3.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_PT_UKB_20200608 |
PPM001217 | PGS000532 (PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.49 [1.451, 1.529] β: 0.399 (0.0134) |
AUROC: 0.608 [0.601, 0.615] | Nagelkerke's Pseudo-R²: 0.0285 Brier score: 0.0816 Odds Ratio (OR, top 1% vs. Rest): 3.0 [2.54, 3.54] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-positive-BRCA_LASSOSUM_UKB_20200608 |
PPM001218 | PGS000533 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.489 [1.401, 1.583] β: 0.398 (0.0312) |
AUROC: 0.607 [0.591, 0.623] | Nagelkerke's Pseudo-R²: 0.0354 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.51 [1.63, 3.86] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_P_5e-08_MGI_20200608 |
PPM001220 | PGS000535 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.568 [1.473, 1.668] β: 0.45 (0.0317) |
AUROC: 0.622 [0.605, 0.638] | Nagelkerke's Pseudo-R²: 0.0443 Brier score: 0.135 Odds Ratio (OR, top 1% vs. Rest): 3.43 [2.32, 5.05] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_MGI_20200608 |
PPM001221 | PGS000536 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.571 [1.53, 1.614] β: 0.452 (0.0136) |
AUROC: 0.623 [0.615, 0.63] | Nagelkerke's Pseudo-R²: 0.036 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.54 [3.02, 4.14] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PRS-CS_UKB_20200608 |
PPM001224 | PGS000539 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.585 [1.489, 1.687] β: 0.46 (0.0319) |
AUROC: 0.624 [0.607, 0.641] | Nagelkerke's Pseudo-R²: 0.0464 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.49 [1.61, 3.84] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608 |
PPM001346 | PGS000332 (PRS_BC) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer | HR: 1.63 [1.6, 1.67] | — | — | 10 ancestry PCs, batch, age as time scale | — |
PPM001191 | PGS000506 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.567 [1.526, 1.609] β: 0.449 (0.0134) |
AUROC: 0.622 [0.615, 0.63] | Nagelkerke's Pseudo-R²: 0.0361 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.69 [3.16, 4.31] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_P_5e-08_UKB_20200608 |
PPM001193 | PGS000508 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.756 [1.709, 1.804] β: 0.563 (0.0138) |
AUROC: 0.652 [0.645, 0.658] | Nagelkerke's Pseudo-R²: 0.0548 Brier score: 0.0805 Odds Ratio (OR, top 1% vs. Rest): 4.38 [3.79, 5.07] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PRS-CS_UKB_20200608 |
PPM001194 | PGS000509 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.643 [1.542, 1.75] β: 0.496 (0.0323) |
AUROC: 0.635 [0.618, 0.651] | Nagelkerke's Pseudo-R²: 0.0532 Brier score: 0.135 Odds Ratio (OR, top 1% vs. Rest): 2.84 [1.88, 4.28] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_PT_MGI_20200608 |
PPM001196 | PGS000511 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.7 [1.594, 1.813] β: 0.53 (0.0328) |
AUROC: 0.641 [0.625, 0.656] | Nagelkerke's Pseudo-R²: 0.0592 Brier score: 0.134 Odds Ratio (OR, top 1% vs. Rest): 2.48 [1.63, 3.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_MGI_20200608 |
PPM001197 | PGS000512 (PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.699 [1.654, 1.746] β: 0.53 (0.0138) |
AUROC: 0.643 [0.637, 0.65] | Nagelkerke's Pseudo-R²: 0.0487 Brier score: 0.0807 Odds Ratio (OR, top 1% vs. Rest): 4.02 [3.46, 4.67] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-Overall-BRCA_LASSOSUM_UKB_20200608 |
PPM001199 | PGS000514 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PRS-CS_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.391 [1.309, 1.478] β: 0.33 (0.031) |
AUROC: 0.59 [0.573, 0.607] | Nagelkerke's Pseudo-R²: 0.0248 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.79 [1.12, 2.86] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PRS-CS_MGI_20200608 |
PPM001200 | PGS000515 (PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PT_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.453 [1.367, 1.544] β: 0.374 (0.0311) |
AUROC: 0.605 [0.588, 0.621] | Nagelkerke's Pseudo-R²: 0.0307 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.09 [1.31, 3.32] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_UKBB-SAIGE-HRC-X174.1_PT_MGI_20200608 |
PPM001202 | PGS000517 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.229 [1.157, 1.305] β: 0.206 (0.0306) |
AUROC: 0.55 [0.533, 0.566] | Nagelkerke's Pseudo-R²: 0.0097 Brier score: 0.139 Odds Ratio (OR, top 1% vs. Rest): 1.88 [1.17, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_MGI_20200608 |
PPM001203 | PGS000518 (PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.18 [1.15, 1.21] β: 0.165 (0.0131) |
AUROC: 0.542 [0.534, 0.55] | Nagelkerke's Pseudo-R²: 0.00504 Brier score: 0.0826 Odds Ratio (OR, top 1% vs. Rest): 1.49 [1.2, 1.86] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-ER-negative-BRCA_P_5e-08_UKB_20200608 |
PPM001185 | PGS000500 (PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.674 [1.63, 1.719] β: 0.515 (0.0137) |
AUROC: 0.64 [0.634, 0.647] | Nagelkerke's Pseudo-R²: 0.0463 Brier score: 0.0809 Odds Ratio (OR, top 1% vs. Rest): 3.64 [3.12, 4.25] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_Onco-iCOGS-ER-positive-BRCA_PRS-CS_UKB_20200608 |
PPM001165 | PGS000480 (PRSWEB_PHECODE174.1_C50_P_5e-08_MGI_20200608) |
PSS000549| European Ancestry| 7,785 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.33 [1.253, 1.412] β: 0.285 (0.0304) |
AUROC: 0.576 [0.559, 0.593] | Nagelkerke's Pseudo-R²: 0.0186 Brier score: 0.138 Odds Ratio (OR, top 1% vs. Rest): 1.91 [1.2, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_C50_P_5e-08_MGI_20200608 |
PPM001223 | PGS000538 (PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608) |
PSS000570| European Ancestry| 68,531 individuals |
PGP000118 | Fritsche LG et al. Am J Hum Genet (2020) |
Reported Trait: Breast cancer [female] | OR: 1.448 [1.411, 1.486] β: 0.37 (0.0132) |
AUROC: 0.602 [0.594, 0.609] | Nagelkerke's Pseudo-R²: 0.025 Brier score: 0.0818 Odds Ratio (OR, top 1% vs. Rest): 2.78 [2.34, 3.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE174.1_iCOGS-Overall-BRCA_PT_UKB_20200608 |
PPM001348 | PGS000332 (PRS_BC) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer | OR: 1.71 [1.67, 1.75] | — | — | Age, 10 ancestry PCs, batch | — |
PPM000849 | PGS000317 (PRS180) |
PSS000407| Hispanic or Latin American Ancestry| 2,001 individuals |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Reported Trait: Breast cancer (Latin american women) | OR: 1.54 [1.45, 1.63] | AUROC: 0.62 [0.61, 0.64] | — | study, genetic ancestry (ADMIXTURE) | — |
PPM000654 | PGS000005 (PRS313_ERpos) |
PSS000361| European Ancestry| 22,594 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B/HER2-negative-like) | OR: 1.62 [1.54, 1.7] | AUROC: 0.6323 | — | — | — |
PPM000903 | PGS000335 (BC_PRSCS) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |
Reported Trait: Breast cancer | OR: 1.8 [1.76, 1.84] | — | — | Age, 10 ancestry PCs, batch | — |
PPM000889 | PGS000332 (PRS_BC) |
PSS000443| European Ancestry| 76,173 individuals |
PGP000100 | Mars N et al. Nat Med (2020) |
Reported Trait: Breast cancer (incident and prevalent cases) | HR: 1.64 [1.6, 1.69] | — | — | genotyping array/batch, 10 ancestry PCs | — |
PPM000848 | PGS000317 (PRS180) |
PSS000408| Hispanic or Latin American Ancestry| 7,317 individuals |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Reported Trait: Breast cancer (US Latinas) | OR: 1.62 [1.52, 1.71] | AUROC: 0.63 [0.62, 0.65] | — | study, genetic ancestry (ADMIXTURE) | — |
PPM000846 | PGS000317 (PRS180) |
PSS000406| Hispanic or Latin American Ancestry| 12,280 individuals |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Reported Trait: Breast cancer | OR: 1.58 [1.52, 1.64] | AUROC: 0.63 [0.62, 0.64] | — | study, genetic ancestry (ADMIXTURE) | — |
PPM000902 | PGS000335 (BC_PRSCS) |
PSS000450| European Ancestry| 122,978 individuals |
PGP000102 | Mars N et al. Nat Commun (2020) |
Reported Trait: Breast cancer | HR: 1.71 [1.68, 1.75] | — | — | 10 ancestry PCs, batch, age as time scale | — |
PPM000663 | PGS000005 (PRS313_ERpos) |
PSS000363| European Ancestry| 22,821 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (triple negative) | OR: 1.59 [1.51, 1.66] | AUROC: 0.6276 | — | — | — |
PPM000662 | PGS000004 (PRS313_BC) |
PSS000363| European Ancestry| 22,821 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (triple negative) | OR: 1.38 [1.31, 1.44] | AUROC: 0.5877 | — | — | — |
PPM000661 | PGS000216 (PRS330_TN) |
PSS000363| European Ancestry| 22,821 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (triple negative) | OR: 1.65 [1.57, 1.73] | AUROC: 0.6358 | — | — | — |
PPM000660 | PGS000005 (PRS313_ERpos) |
PSS000359| European Ancestry| 21,533 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (HER2-enriched-like) | OR: 1.59 [1.48, 1.71] | AUROC: 0.6291 | — | — | — |
PPM000659 | PGS000004 (PRS313_BC) |
PSS000359| European Ancestry| 21,533 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (HER2-enriched-like) | OR: 1.49 [1.38, 1.6] | AUROC: 0.6093 | — | — | — |
PPM000658 | PGS000215 (PRS330_HER2) |
PSS000359| European Ancestry| 21,533 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (HER2-enriched-like) | OR: 1.53 [1.42, 1.65] | AUROC: 0.6208 | — | — | — |
PPM000657 | PGS000005 (PRS313_ERpos) |
PSS000362| European Ancestry| 22,497 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B-like) | OR: 1.66 [1.58, 1.75] | AUROC: 0.64 | — | — | — |
PPM000656 | PGS000004 (PRS313_BC) |
PSS000362| European Ancestry| 22,497 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B-like) | OR: 1.68 [1.6, 1.77] | AUROC: 0.6432 | — | — | — |
PPM000655 | PGS000214 (PRS330_LumB) |
PSS000362| European Ancestry| 22,497 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B-like) | OR: 1.69 [1.61, 1.77] | AUROC: 0.6431 | — | — | — |
PPM000653 | PGS000004 (PRS313_BC) |
PSS000361| European Ancestry| 22,594 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B/HER2-negative-like) | OR: 1.62 [1.55, 1.71] | AUROC: 0.6336 | — | — | — |
PPM000652 | PGS000213 (PRS330_LumBHER2neg) |
PSS000361| European Ancestry| 22,594 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (luminal B/HER2-negative-like) | OR: 1.62 [1.54, 1.7] | AUROC: 0.633 | — | — | — |
PPM000651 | PGS000005 (PRS313_ERpos) |
PSS000360| European Ancestry| 28,140 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal A-like) | OR: 1.82 [1.77, 1.87] | AUROC: 0.6595 | — | — | — |
PPM000650 | PGS000004 (PRS313_BC) |
PSS000360| European Ancestry| 28,140 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |Ext. |
Reported Trait: Breast cancer intrinsic-like subtype (luminal A-like) | OR: 1.8 [1.75, 1.86] | AUROC: 0.6573 | — | — | — |
PPM000649 | PGS000212 (PRS330_LumA) |
PSS000360| European Ancestry| 28,140 individuals |
PGP000088 | Zhang H et al. Nat Genet (2020) |
Reported Trait: Breast cancer intrinsic-like subtype (luminal A-like) | OR: 1.83 [1.78, 1.88] | AUROC: 0.6609 | — | — | — |
PPM000847 | PGS000317 (PRS180) |
PSS000406| Hispanic or Latin American Ancestry| 12,280 individuals |
PGP000094 | Shieh Y et al. J Natl Cancer Inst (2020) |
Reported Trait: Breast cancer | OR: 1.7 [1.63, 1.78] | — | — | — | — |
PPM001646 | PGS000004 (PRS313_BC) |
PSS000854| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |Ext. |
Reported Trait: Incident breast cancer | — | AUROC: 0.628 [0.62, 0.637] | — | Genotyping array | Missing 25 variants (8%) based on availability of variants in the cohort |
PPM001647 | PGS000004 (PRS313_BC) |
PSS000854| European Ancestry| 400,812 individuals |
PGP000135 | Jia G et al. JNCI Cancer Spectr (2020) |Ext. |
Reported Trait: Incident breast cancer | — | AUROC: 0.633 [0.624, 0.641] | — | family history of cancer (in first-degree relatives), genotyping array | Missing 25 variants (8%) based on availability of variants in the cohort |
PPM001947 | PGS000005 (PRS313_ERpos) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in males | OR: 1.55 [1.45, 1.66] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 4.01 [3.17, 5.06] | — | — |
PPM001948 | PGS000005 (PRS313_ERpos) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in females | OR: 1.5 [1.41, 1.6] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 3.26 [2.64, 4.03] | — | — |
PPM001949 | PGS000006 (PRS313_ERneg) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in males | OR: 1.37 [1.29, 1.47] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 2.39 [1.93, 2.96] | — | — |
PPM001950 | PGS000006 (PRS313_ERneg) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in females | OR: 1.38 [1.29, 1.47] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 2.51 [2.05, 3.07] | — | — |
PPM001945 | PGS000004 (PRS313_BC) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in males | OR: 1.55 [1.45, 1.66] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 3.86 [3.07, 4.87] | — | — |
PPM001946 | PGS000004 (PRS313_BC) |
PSS000974| European Ancestry| 5,714 individuals |
PGP000167 | Maguire S et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer in females | OR: 1.51 [1.42, 1.61] | — | Odds Ratio (OR, top 20% vs. bottom 20%): 3.38 [2.74, 4.18] | — | — |
PPM001958 | PGS000004 (PRS313_BC) |
PSS000979| Multi-ancestry (including European)| 19,264 individuals |
PGP000171 | Fahed AC et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer in carriers of a hereditary breast and ovarian cancer variant | OR: 1.44 [1.19, 1.74] | — | Odds Ratio (OR, top 20% vs bottom 20%): 3.04 [1.61, 5.73] | Age, PCs (1-4) | — |
PPM001959 | PGS000004 (PRS313_BC) |
PSS000979| Multi-ancestry (including European)| 19,264 individuals |
PGP000171 | Fahed AC et al. Nat Commun (2020) |Ext. |
Reported Trait: Breast cancer in non-carriers of a hereditary breast and ovarian cancer variant | OR: 1.57 [1.49, 1.65] | — | — | Age, PCs (1-4) | — |
PPM001960 | PGS000004 (PRS313_BC) |
PSS000980| Multi-ancestry (including European)| 26,595 individuals |
PGP000171 | Fahed AC et al. Nat Commun (2020) |Ext. |
Reported Trait: Prevalent breast cancer | OR: 1.61 [1.52, 1.7] | — | — | Age, PCs (1-4) | — |
PPM005169 | PGS000007 (PRS3820_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.59 [0.58, 0.6] | R²: 0.021 | — | — |
PPM001999 | PGS000004 (PRS313_BC) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.27 [1.23, 1.31] | — | Odds Ratio (OR, top 10% vs. middle 20%): 1.54 [1.38, 1.72] | Age, study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
PPM002000 | PGS000004 (PRS313_BC) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.571 [0.562, 0.579] | — | Study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
PPM002001 | PGS000005 (PRS313_ERpos) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Estrogen-receptor positive breast cancer | OR: 1.37 [1.32, 1.43] | — | Odds Ratio (OR, top 10% vs. middle 20%): 1.85 [1.61, 2.13] | Age, study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
PPM002002 | PGS000005 (PRS313_ERpos) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Estrogen-receptor positive breast cancer | — | AUROC: 0.588 [0.577, 0.599] | — | Study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
PPM002003 | PGS000006 (PRS313_ERneg) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Estrogen-receptor negative breast cancer | OR: 1.21 [1.15, 1.27] | — | Odds Ratio (OR, top 10% vs. middle 20%): 1.47 [1.25, 1.74] | Age, study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
PPM002004 | PGS000006 (PRS313_ERneg) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Estrogen-receptor negative breast cancer | — | AUROC: 0.562 [0.551, 0.573] | — | Study, PCs(1-10) | Only 224 of the original 313 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies. |
PPM002005 | PGS000773 (PRS179_BC) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Breast cancer | OR: 1.26 [1.22, 1.3] | — | — | Age, study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
PPM002006 | PGS000773 (PRS179_BC) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Breast cancer | — | AUROC: 0.568 [0.56, 0.576] | — | Study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
PPM002007 | PGS000774 (PRS179_ERpos) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Estrogen-receptor positive breast cancer | OR: 1.33 [1.27, 1.38] | — | — | Age, study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
PPM002008 | PGS000774 (PRS179_ERpos) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Estrogen-receptor positive breast cancer | — | AUROC: 0.576 [0.566, 0.585] | — | Study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
PPM002009 | PGS000775 (PRS179_ERneg) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Estrogen-receptor negative breast cancer | OR: 1.31 [1.24, 1.37] | — | — | Age, study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
PPM002010 | PGS000775 (PRS179_ERneg) |
PSS000995| Multi-ancestry (excluding European)| 19,434 individuals |
PGP000179 | Du Z et al. J Natl Cancer Inst (2021) |
Reported Trait: Estrogen-receptor negative breast cancer | — | AUROC: 0.578 [0.564, 0.591] | — | Study, PCs(1-10) | Only 163 of the original 179 SNPs were avaialble in all consortia (imputation score r^2 < 0.8).For missing variants (not genotyped or imputed) in one study, each individual in that study was assigned the expected dosage derived from the remainder of studies |
PPM002152 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers 40 years of age or below | HR: 1.43 [1.04, 1.97] | — | — | Year of birth, counselling center of origin | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
PPM002156 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers | HR: 1.9 [1.32, 2.75] | — | — | Year of birth, counselling center of origin, PRS*c.1100delC carrier status | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
PPM002054 | PGS000783 (CC_Breast_IV) |
PSS001011| European Ancestry| 216,273 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident breast cancer | HR: 1.52 [1.47, 1.56] | AUROC: 0.637 C-index: 0.635 (0.004) |
R²: 0.146 | Age at assessment, family history of breast cancer, genotyping array, PCs(1-15), parity( ≥1 live birth vs. none), age at menarche, body mass index, menopausal status (pre-menopausal vs. post-menopausal vs. unknown or hysterectomy), ever used hormone replacement therapy, oral contraceptive use, alcool intake, (Body mass index)*(menopausal status) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
PPM002038 | PGS000072 (CC_Breast) |
PSS001011| European Ancestry| 216,273 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |Ext. |
Reported Trait: Incident breast cancer | HR: 1.52 [1.47, 1.56] | AUROC: 0.637 C-index: 632.0 (0.005) |
— | Age at assessment, family history of breast cancer, genotyping array, PCs(1-15), parity( ≥1 live birth vs. none), age at menarche, body mass index, menopausal status (pre-menopausal vs. post-menopausal vs. unknown or hysterectomy), ever used hormone replacement therapy, oral contraceptive use, alcool intake, body mass index*menopausal status | Only 162 of the original 187 SNPs used based on those that reached p<5e-8 in the BCAC meta-analysis. C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
PPM002070 | PGS000783 (CC_Breast_IV) |
PSS001011| European Ancestry| 216,273 individuals |
PGP000186 | Kachuri L et al. Nat Commun (2020) |
Reported Trait: Incident breast cancer | — | AUROC: 0.626 C-index: 0.62 (0.005) |
R²: 0.122 | Age, genotyping array, PCs(1-15) | C-index calculated as a weighted average between 1 and 5 years and AUC at 5 years. |
PPM002150 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers | HR: 1.71 [1.36, 2.15] | — | — | Year of birth, counselling center of origin | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
PPM002151 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers | HR: 2.29 [1.56, 3.38] | — | — | Year of birth, counselling center of origin, PRS*c.1100delC carrier status | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
PPM002153 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers between 41 and 50 years of age | HR: 2.32 [1.69, 3.2] | — | — | Year of birth, counselling center of origin | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
PPM002154 | PGS000001 (PRS77_BC) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers between 51 and 60 years of age | HR: 1.59 [1.07, 2.35] | — | — | Year of birth, counselling center of origin | Only 70 of the original 77 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 70 SNPs used, 7 were proxies R^2>0.8. |
PPM002155 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers | HR: 1.71 [1.37, 2.13] | — | — | Year of birth, counselling center of origin | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
PPM002157 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers 40 years of age or below | HR: 1.59 [1.2, 2.11] | — | — | Year of birth, counselling center of origin | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
PPM002158 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers between 41 and 50 years of age | HR: 2.07 [1.53, 2.82] | — | — | Year of birth, counselling center of origin | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
PPM002159 | PGS000045 (BCPRS_Overall) |
PSS001054| European Ancestry| 760 individuals |
PGP000198 | Borde J et al. J Natl Cancer Inst (2020) |Ext. |
Reported Trait: Breast cancer in CHEK2 mutation carriers between 51 and 60 years of age | HR: 1.56 [1.05, 2.31] | — | — | Year of birth, counselling center of origin | Only 81 of the original 88 SNPs were used due to a call rate below 0.95 or significant association with c.1100delC carrier status. Of the 81 SNPs used, 7 were proxies R^2>0.8. |
PPM005170 | PGS000015 (GPS_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.61 [0.6, 0.62] | R²: 0.017 | — | — |
PPM002456 | PGS000873 (SNP143) |
PSS001111| Ancestry Not Reported| 2,073 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.12 [1.81, 2.49] | Age | — |
PPM002458 | PGS000873 (SNP143) |
PSS001105| Ancestry Not Reported| 2,021 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor positive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.17 [1.83, 2.58] | Age | — |
PPM002460 | PGS000873 (SNP143) |
PSS001108| Ancestry Not Reported| 1,707 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor negative breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 1.86 [1.18, 2.91] | Age | — |
PPM002462 | PGS000873 (SNP143) |
PSS001113| Ancestry Not Reported| 1,991 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Invasive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.14 [1.79, 2.55] | Age | — |
PPM002464 | PGS000873 (SNP143) |
PSS001112| Ancestry Not Reported| 1,750 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 2.0 [1.46, 2.75] | Age | — |
PPM002466 | PGS000873 (SNP143) |
PSS001107| Ancestry Not Reported| 1,956 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Invasive estrogen-receptor positive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.55 [1.86, 2.7] | Age | — |
PPM002468 | PGS000873 (SNP143) |
PSS001106| Ancestry Not Reported| 1,733 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor positive breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 1.84 [1.3, 2.6] | Age | — |
PPM002470 | PGS000873 (SNP143) |
PSS001110| Ancestry Not Reported| 1,694 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Invasive estrogen-receptor negative breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 1.44 [0.84, 2.47] | Age | — |
PPM002471 | PGS000873 (SNP143) |
PSS001109| Ancestry Not Reported| 1,681 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor negative breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 3.12 [1.41, 6.88] | Age | — |
PPM005171 | PGS000004 (PRS313_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.55 [0.51, 0.58] | R²: 0.0003 | — | — |
PPM005172 | PGS000007 (PRS3820_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.53 [0.5, 0.57] | R²: 0.0002 | — | — |
PPM005118 | PGS000004 (PRS313_BC) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA1 carriers | OR: 1.4 [1.06, 1.85] | — | — | PCs(1-3) | — |
PPM005167 | PGS000317 (PRS180) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.2 [1.0, 1.46] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
PPM005168 | PGS000004 (PRS313_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.6 [0.59, 0.61] | R²: 0.025 | — | — |
PPM005176 | PGS000317 (PRS180) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.54 [0.47, 0.62] | R²: 0.05 | — | — |
PPM005127 | PGS000005 (PRS313_ERpos) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA1 carriers | OR: 1.4 [1.07, 1.83] | AUROC: 0.6 [0.51, 0.69] | — | PCs(1-3) | — |
PPM005128 | PGS000005 (PRS313_ERpos) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA1 carriers | OR: 1.39 [1.06, 1.82] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
PPM005129 | PGS000005 (PRS313_ERpos) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA1 carriers | OR: 1.46 [1.09, 1.94] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
PPM005130 | PGS000005 (PRS313_ERpos) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA2 carriers | OR: 1.33 [1.16, 1.52] | AUROC: 0.59 [0.55, 0.63] | — | PCs(1-3) | — |
PPM005131 | PGS000005 (PRS313_ERpos) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA2 carriers | OR: 1.33 [1.16, 1.53] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
PPM005148 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Incident invasive estrogen receptor postivie/progesterone receptor positive breast cancer | HR: 1.53 [1.22, 1.91] | — | — | Family history of breast cancer (first-degree blood relatives), treatment (asprin/placebo), age at enrolment, number of children, alcohol use, body mass index at enrolment, use of hormone replacement therapy at enrolment | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
PPM005150 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Diagnosis of prevalent invasive breast cancer before the age of 50 | OR: 1.39 [1.08, 1.8] | — | — | Family history of breast cancer (first-degree blood relatives) | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
PPM005151 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Diagnosis of prevalent invasive breast cancer at the age of 50 or over | OR: 1.47 [1.33, 1.63] | — | — | Family history of breast cancer (first-degree blood relatives) | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
PPM005124 | PGS000006 (PRS313_ERneg) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor negative breast cancer in BRCA2 carriers | OR: 1.23 [1.07, 1.41] | — | — | PCs(1-3) | — |
PPM005125 | PGS000006 (PRS313_ERneg) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor negative breast cancer in BRCA2 carriers | OR: 1.23 [1.07, 1.42] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
PPM005159 | PGS000004 (PRS313_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.4 [1.35, 1.45] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
PPM005160 | PGS000007 (PRS3820_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.36 [1.31, 1.41] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
PPM005161 | PGS000015 (GPS_BC) |
PSS003599| European Ancestry| 33,954 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.46 [1.41, 1.51] | — | Odds Ratio (OR, top 1% vs middle 20%): 2.48 [1.89, 3.25] | Age, family history, study site, 3 ancestry-specific PCs | — |
PPM005162 | PGS000004 (PRS313_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.26 [1.1, 1.44] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
PPM005163 | PGS000007 (PRS3820_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.21 [1.06, 1.39] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
PPM005164 | PGS000015 (GPS_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.24 [1.08, 1.43] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
PPM005165 | PGS000004 (PRS313_BC) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.3 [1.08, 1.57] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
PPM005166 | PGS000015 (GPS_BC) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | OR: 1.35 [1.11, 1.64] | — | — | Age, family history, study site, 3 ancestry-specific PCs | — |
PPM005173 | PGS000015 (GPS_BC) |
PSS003598| African Ancestry| 3,801 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.55 [0.52, 0.59] | R²: 0.0004 | — | — |
PPM005174 | PGS000004 (PRS313_BC) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.55 [0.5, 0.6] | R²: 0.0008 | — | — |
PPM005175 | PGS000015 (GPS_BC) |
PSS003600| Hispanic or Latin American Ancestry| 2,196 individuals |
PGP000249 | Liu C et al. JAMA Netw Open (2021) |Ext. |
Reported Trait: Breast cancer | — | AUROC: 0.56 [0.51, 0.6] | R²: 0.001 | — | — |
PPM005119 | PGS000004 (PRS313_BC) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA1 carriers | OR: 1.39 [1.05, 1.84] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
PPM005120 | PGS000004 (PRS313_BC) |
PSS003581| European Ancestry| 413 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA1 carriers | OR: 1.44 [1.07, 1.95] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
PPM005121 | PGS000004 (PRS313_BC) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA2 carriers | OR: 1.32 [1.15, 1.52] | — | — | PCs(1-3) | — |
PPM005122 | PGS000004 (PRS313_BC) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA2 carriers | OR: 1.33 [1.15, 1.52] | — | — | PCs(1-3), family history of male breast cancer in first and second degree relatives | — |
PPM005123 | PGS000004 (PRS313_BC) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male breast cancer in BRCA2 carriers | OR: 1.36 [1.18, 1.57] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
PPM005126 | PGS000006 (PRS313_ERneg) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor negative breast cancer in BRCA2 carriers | OR: 1.25 [1.09, 1.45] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
PPM005132 | PGS000005 (PRS313_ERpos) |
PSS003582| European Ancestry| 1,177 individuals |
PGP000245 | Barnes DR et al. J Natl Cancer Inst (2021) |Ext. |
Reported Trait: Male estrogen receptor positive breast cancer in BRCA2 carriers | OR: 1.36 [1.18, 1.57] | — | — | PCs(1-3), family history of female breast cancer in first and second degree relatives | — |
PPM005147 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Incident invasive breast cancer | HR: 1.43 [1.18, 1.73] | C-index: 0.65 [0.59, 0.71] | Hazard Ratio (HR, top 20% vs bottom 20%): 2.16 [1.21, 3.86] | Family history of breast cancer (first-degree blood relatives), treatment (asprin/placebo), age at enrolment, number of children, alcohol use, body mass index at enrolment, use of hormone replacement therapy at enrolment | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
PPM005149 | PGS000004 (PRS313_BC) |
PSS003595| European Ancestry| 6,339 individuals |
PGP000247 | Lacaze P et al. Cancers (Basel) (2021) |Ext. |
Reported Trait: Prevalent invasive breast cancer | OR: 1.47 [1.34, 1.61] | AUROC: 0.62 [0.59, 0.65] | Odds Ratio (OR, top 20% vs bottom 20%): 3.16 [2.26, 4.49] | Family history of breast cancer (first-degree blood relatives), pathogenic variants in breast cancer-associated genes | Only 271 SNPs from PGS000004 were utilised. 42 SNPs were not included due to low imputation quality scores (r^2 < 0.3). |
PPM009262 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | OR: 1.66 [1.25, 2.2] | AUROC: 0.548 | — | Age | — |
PPM009264 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | OR: 1.57 [1.18, 2.08] | AUROC: 0.578 | — | Age, family history | — |
PPM009261 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | OR: 1.66 [1.25, 2.19] | AUROC: 0.547 [0.52, 0.57] | — | — | — |
PPM009263 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | OR: 1.56 [1.18, 2.08] | AUROC: 0.578 | — | Family history | — |
PPM009265 | PGS001778 (PRS15_BC) |
PSS007670| European Ancestry| 1,780 individuals |
PGP000259 | Yiangou K et al. Cancers (Basel) (2021) |
Reported Trait: Breast cancer | — | AUROC: 0.6975 [0.673, 0.722] | Odds Ratio (OR, top 10% vs middle10%): 4.58 [2.88, 7.4] | Age at interview, menopausal status, age at menarche, age at first full-term pregnancy(1-4), parous, breast feeding, smoking status, body mass index, height, hormone-replacement therapy ever use, family history | — |
PPM009166 | PGS001336 (GBE_cancer1002) |
PSS007616| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.79293 [0.76728, 0.81858] | R²: 0.15047 Incremental AUROC (full-covars): 0.01474 PGS R2 (no covariates): 0.00598 PGS AUROC (no covariates): 0.56918 [0.51783, 0.62054] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM009167 | PGS001336 (GBE_cancer1002) |
PSS007617| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.7602 [0.71475, 0.80565] | R²: 0.14344 Incremental AUROC (full-covars): 0.01509 PGS R2 (no covariates): 0.01507 PGS AUROC (no covariates): 0.59411 [0.51563, 0.67258] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM009168 | PGS001336 (GBE_cancer1002) |
PSS007618| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.80561 [0.79545, 0.81577] | R²: 0.18447 Incremental AUROC (full-covars): 0.01345 PGS R2 (no covariates): 0.01264 PGS AUROC (no covariates): 0.58544 [0.56669, 0.6042] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM009169 | PGS001336 (GBE_cancer1002) |
PSS007619| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.83564 [0.81289, 0.85838] | R²: 0.18535 Incremental AUROC (full-covars): 0.00869 PGS R2 (no covariates): 0.00739 PGS AUROC (no covariates): 0.5725 [0.52745, 0.61755] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM009170 | PGS001336 (GBE_cancer1002) |
PSS007620| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Breast cancer | — | AUROC: 0.80961 [0.80348, 0.81573] | R²: 0.1894 Incremental AUROC (full-covars): 0.02139 PGS R2 (no covariates): 0.01602 PGS AUROC (no covariates): 0.59627 [0.58498, 0.60756] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
PPM009338 | PGS001804 (portability-PLR_174.1) |
PSS009274| European Ancestry| 10,197 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1101 [0.0908, 0.1292] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009339 | PGS001804 (portability-PLR_174.1) |
PSS009048| European Ancestry| 2,440 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0843 [0.0446, 0.1237] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009340 | PGS001804 (portability-PLR_174.1) |
PSS008602| European Ancestry| 3,484 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1125 [0.0795, 0.1453] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009343 | PGS001804 (portability-PLR_174.1) |
PSS007944| East Asian Ancestry| 1,143 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0983 [0.0401, 0.1559] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009344 | PGS001804 (portability-PLR_174.1) |
PSS007726| African Ancestry| 1,482 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0416 [-0.0097, 0.0927] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009345 | PGS001804 (portability-PLR_174.1) |
PSS008828| African Ancestry| 2,035 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0889 [0.0454, 0.132] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM010994 | PGS002015 (portability-ldpred2_174.1) |
PSS009274| European Ancestry| 10,197 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1132 [0.094, 0.1324] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM010995 | PGS002015 (portability-ldpred2_174.1) |
PSS009048| European Ancestry| 2,440 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0807 [0.041, 0.1201] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM010996 | PGS002015 (portability-ldpred2_174.1) |
PSS008602| European Ancestry| 3,484 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1091 [0.076, 0.1419] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM010997 | PGS002015 (portability-ldpred2_174.1) |
PSS008380| Greater Middle Eastern Ancestry| 467 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0976 [0.005, 0.1885] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM010998 | PGS002015 (portability-ldpred2_174.1) |
PSS008156| South Asian Ancestry| 2,782 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0798 [0.0426, 0.1167] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM010999 | PGS002015 (portability-ldpred2_174.1) |
PSS007944| East Asian Ancestry| 1,143 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.1146 [0.0565, 0.1719] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011000 | PGS002015 (portability-ldpred2_174.1) |
PSS007726| African Ancestry| 1,482 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0482 [-0.0031, 0.0992] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM011001 | PGS002015 (portability-ldpred2_174.1) |
PSS008828| African Ancestry| 2,035 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0842 [0.0407, 0.1274] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009341 | PGS001804 (portability-PLR_174.1) |
PSS008380| Greater Middle Eastern Ancestry| 467 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0772 [-0.0155, 0.1687] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM009342 | PGS001804 (portability-PLR_174.1) |
PSS008156| South Asian Ancestry| 2,782 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Breast cancer [female] | — | — | Partial Correlation (partial-r): 0.0673 [0.0301, 0.1044] | sex, age, birth date, deprivation index, 16 PCs | — |
PPM012734 | PGS002242 (ldpred_breastcancer) |
PSS009523| European Ancestry| 258,402 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.48 [1.45, 1.51] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012738 | PGS002242 (ldpred_breastcancer) |
PSS009519| European Ancestry| 110,597 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.45 [1.37, 1.53] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012742 | PGS002242 (ldpred_breastcancer) |
PSS009515| East Asian Ancestry| 178,726 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.25 [1.21, 1.28] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012746 | PGS002242 (ldpred_breastcancer) |
PSS009527| European Ancestry| 69,422 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.5 [1.43, 1.58] | — | — | birth year, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012750 | PGS002242 (ldpred_breastcancer) |
PSS009535| European Ancestry| 25,696 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.45 [1.38, 1.54] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012754 | PGS002242 (ldpred_breastcancer) |
PSS009531| African Ancestry| 1,535 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 0.9 [0.69, 1.17] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012758 | PGS002242 (ldpred_breastcancer) |
PSS009543| European Ancestry| 343,676 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.5 [1.47, 1.53] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012763 | PGS002242 (ldpred_breastcancer) |
PSS009539| African Ancestry| 7,618 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.12 [0.93, 1.35] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012768 | PGS002242 (ldpred_breastcancer) |
PSS009547| South Asian Ancestry| 7,628 individuals |
PGP000271 | Mars N et al. Cell Genom (2022) |
Reported Trait: Breast cancer | OR: 1.47 [1.23, 1.75] | — | — | age, 10 PCs (+/- dataset-specific technical covariates) | — |
PPM012885 | PGS000004 (PRS313_BC) |
PSS009592| Ancestry Not Reported| 5,023 individuals |
PGP000292 | Saad M et al. Lancet Oncol (2022) |Ext. |
Reported Trait: Breast cancer | OR: 1.432 [1.333, 1.538] | AUROC: 0.6 [0.581, 0.62] | — | — | — |
PPM012909 | PGS000004 (PRS313_BC) |
PSS009609| European Ancestry| 54,949 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: Incident primary breast cancer | — | AUROC: 0.631 [0.61, 0.651] | Calibration (E/O): 0.9 [0.7, 1.0] | — | — |
PPM012910 | PGS000004 (PRS313_BC) |
PSS009610| European Ancestry| 238,663 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: Incident primary breast cancer | — | AUROC: 0.622 [0.614, 0.63] | Calibration (E/O): 1.0 [0.7, 1.3] | — | — |
PPM012912 | PGS000004 (PRS313_BC) |
PSS009610| European Ancestry| 238,663 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: Incident primary breast cancer | — | AUROC: 0.64 [0.632, 0.647] | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
PPM012913 | PGS000004 (PRS313_BC) |
PSS009611| European Ancestry| 302,425 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.668 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
PPM012914 | PGS000004 (PRS313_BC) |
PSS009612| European Ancestry| 840,867 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.664 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
PPM012915 | PGS000004 (PRS313_BC) |
PSS009613| European Ancestry| 408,679 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.666 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
PPM013021 | PGS002294 (PRS111) |
PSS009652| East Asian Ancestry| 1,104 individuals |
PGP000324 | Yang Y et al. JAMA Netw Open (2022) |
Reported Trait: Breast cancer | OR: 1.67 [1.46, 1.92] | AUROC: 0.639 [0.604, 0.674] | — | — | — |
PPM012916 | PGS000004 (PRS313_BC) |
PSS009614| European Ancestry| 188,453 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.661 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
PPM012917 | PGS000004 (PRS313_BC) |
PSS009615| European Ancestry| 1,401,091 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.664 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
PPM012918 | PGS000004 (PRS313_BC) |
PSS009616| European Ancestry| 5,328,392 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: 5-year absolute risk breast cancer (>3%) | — | AUROC: 0.665 | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
PPM012911 | PGS000004 (PRS313_BC) |
PSS009609| European Ancestry| 54,949 individuals |
PGP000297 | Hurson AN et al. Int J Epidemiol (2022) |Ext. |
Reported Trait: Incident primary breast cancer | — | AUROC: 0.64 [0.62, 0.66] | — | iCARE-Lit (Age at menarche, age at first live birth, parity, oral-contraceptive use, age at menopause, hormone-replacement-therapy use, type of hormone replacement therapy, alcohol intake, height, BMI, breast-cancer family history [i.e. presence or absence of breast cancer in at least one first-degree relative] and benign breast disease) | — |
PPM017165 | PGS000072 (CC_Breast) |
PSS010142| European Ancestry| 1,990 individuals |
PGP000443 | Byrne S et al. Int J Epidemiol (2023) |Ext. |
Reported Trait: Post-menopausal breast cancer | HR: 1.26 [1.2, 1.32] | — | — | age at baseline, sex (where relevant), assessment centre, 40 principal components of ancestries (PCs), Townsend Index, education, birth location, income, lifestyle index, additional cancer-specific covariates | — |
PPM014912 | PGS000045 (BCPRS_Overall) |
PSS009925| Ancestry Not Reported| 295 individuals |
PGP000355 | Borde J et al. BMC Cancer (2022) |Ext. |
Reported Trait: Breast cancer in BRAC1 PV carriers | OR: 1.62 [1.16, 2.31] | — | — | — | effective SNP set size of N=77 |
PPM014913 | PGS000047 (BCPRS_ER-) |
PSS009925| Ancestry Not Reported| 295 individuals |
PGP000355 | Borde J et al. BMC Cancer (2022) |Ext. |
Reported Trait: Estrogen receptor [ER]-negative breast cancer in BRAC2 PV carriers | OR: 2.27 [1.45, 3.78] | — | — | — | effective SNP set size of N=50 |
PPM014886 | PGS000004 (PRS313_BC) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus Mammogram Risk Scores | β: 0.061 [0.017, 0.105] | — | — | first 10 principal components | — |
PPM014887 | PGS000004 (PRS313_BC) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus percent Mammogram Risk Scores | β: 0.06 [0.016, 0.104] | — | — | first 10 principal components | — |
PPM014888 | PGS000004 (PRS313_BC) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Altocumulus Mammogram Risk Scores | β: 0.081 [0.037, 0.125] | — | — | first 10 principal components | — |
PPM014889 | PGS000004 (PRS313_BC) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cirrocumulus Mammogram Risk Scores | β: 0.058 [0.016, 0.101] | — | — | first 10 principal components | — |
PPM014890 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus Mammogram Risk Scores | β: 0.059 [0.015, 0.103] | — | — | first 10 principal components | — |
PPM014892 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Altocumulus Mammogram Risk Scores | β: 0.068 [0.024, 0.112] | — | — | first 10 principal components | — |
PPM014893 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cirrocumulus Mammogram Risk Scores | β: 0.046 [0.003, 0.089] | — | — | first 10 principal components | — |
PPM014894 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus-white Mammogram Risk Scores | β: 0.045 [0.002, 0.089] | — | — | first 10 principal components | — |
PPM014895 | PGS000005 (PRS313_ERpos) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus Mammogram Risk Scores | β: 0.056 [0.012, 0.1] | — | — | first 10 principal components | — |
PPM014896 | PGS000005 (PRS313_ERpos) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus percent Mammogram Risk Scores | β: 0.055 [0.011, 0.099] | — | — | first 10 principal components | — |
PPM014897 | PGS000005 (PRS313_ERpos) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Altocumulus Mammogram Risk Scores | β: 0.078 [0.034, 0.121] | — | — | first 10 principal components | — |
PPM014898 | PGS000005 (PRS313_ERpos) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cirrocumulus Mammogram Risk Scores | β: 0.056 [0.014, 0.099] | — | — | first 10 principal components | — |
PPM014891 | PGS000006 (PRS313_ERneg) |
PSS009919| Ancestry Not Reported| 2,559 individuals |
PGP000351 | Li S et al. Cancers (Basel) (2022) |Ext. |
Reported Trait: Cumulus percent Mammogram Risk Scores | β: 0.065 [0.021, 0.109] | — | — | first 10 principal components | — |
PPM015517 | PGS000007 (PRS3820_BC) |
PSS009971| Multi-ancestry (including European)| 36,422 individuals |
PGP000381 | Hao L et al. Nat Med (2022) |Ext. |
Reported Trait: Breast cancer | OR: 2.38 [2.07, 2.73] | — | — | 4 genetic PCs | — |
PPM015579 | PGS000004 (PRS313_BC) |
PSS009990| Multi-ancestry (including European)| 207,510 individuals |
PGP000389 | Giardiello D et al. Breast Cancer Res (2022) |Ext. |
Reported Trait: Contralateral breast cancer | — | — | Subdistributional hazard ratio (sHR, 75th vs. 25th quartile): 1.35 [1.31, 1.39] | PredictCBC-2.0A | Calculated with PredictCBC-2.0A |
PPM016281 | PGS003397 (PRS-42ASN) |
PSS010095| East Asian Ancestry| 41,031 individuals |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Reported Trait: Occurrence of breast cancer | HR: 1.4 [1.3, 1.51] | AUROC: 0.6 [0.58, 0.62] | — | principal component | — |
PPM016282 | PGS003398 (PRS-136EUR) |
PSS010095| East Asian Ancestry| 41,031 individuals |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Reported Trait: Occurrence of breast cancer | HR: 1.55 [1.44, 1.66] | AUROC: 0.62 [0.6, 0.64] | — | principal component | — |
PPM016280 | PGS003396 (PRS-11ASN) |
PSS010095| East Asian Ancestry| 41,031 individuals |
PGP000415 | Jee YH et al. Int J Epidemiol (2022) |
Reported Trait: Occurrence of breast cancer | HR: 1.35 [1.25, 1.45] | AUROC: 0.58 [0.56, 0.61] | — | principal component | — |
PPM016255 | PGS003380 (best_BRCA) |
PSS010074| European Ancestry| 154,361 individuals |
PGP000413 | Namba S et al. Cancer Res (2022) |
Reported Trait: breast cancer | — | AUROC: 0.696 | R²: 0.0555 | age, top 20 genetic principal components | — |
PPM000129 | PGS000051 (PRS67) |
PSS000081| Multi-ancestry (including European)| 8,160 individuals |
PGP000036 | Zhang X et al. PLoS Med (2018) |
Reported Trait: Invasive breast cancer | — | AUROC: 0.678 [0.666, 0.69] | — | Rosner-Colditz BC risk model, Mammographic density (MD), Testoterone (T), estrone sulfate (E1S), prolactin (PRL) | Age-adjusted AUC |
PPM002457 | PGS000873 (SNP143) |
PSS001111| Ancestry Not Reported| 2,073 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.06 [1.75, 2.42] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
PPM002459 | PGS000873 (SNP143) |
PSS001105| Ancestry Not Reported| 2,021 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor positive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.11 [1.78, 2.51] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
PPM002461 | PGS000873 (SNP143) |
PSS001108| Ancestry Not Reported| 1,707 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor negative breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 1.81 [1.16, 2.84] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
PPM002463 | PGS000873 (SNP143) |
PSS001113| Ancestry Not Reported| 1,991 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Invasive breast cancer | — | — | Odds Ratio (OR, per interquartile range unit change): 2.07 [1.74, 2.48] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
PPM002465 | PGS000873 (SNP143) |
PSS001112| Ancestry Not Reported| 1,750 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 1.93 [1.41, 2.65] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
PPM002469 | PGS000873 (SNP143) |
PSS001106| Ancestry Not Reported| 1,733 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor positive breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 1.77 [1.24, 2.51] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
PPM002472 | PGS000873 (SNP143) |
PSS001109| Ancestry Not Reported| 1,681 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reported Trait: Estrogen-receptor negative breast ductal cancer in situ | — | — | Odds Ratio (OR, per interquartile range unit change): 2.99 [1.35, 6.6] | Age, ln(Tyrer-Cuzick model 10-year risk), mammographic density | — |
PPM002467 | PGS000873 (SNP143) |
PSS001107| Ancestry Not Reported| 1,956 individuals |
PGP000216 | Brentnall AR et al. Int J Cancer (2019) |
Reporte |